Directive 98/8/EC of the European Parliament and of the Council (repealed)Show full title

ANNEX I U.K. LIST OF ACTIVE SUBSTANCES WITH REQUIREMENTS AGREED AT COMMUNITY LEVEL FOR INCLUSION IN BIOCIDAL PRODUCTS

a [F2 For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm
b [F3 OJ L 396, 30.12.2006, p. 1 .
c OJ L 158, 30.4.2004, p. 50 .] ] ]
[F1 No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions a
1	sulfuryl fluoride	sulfuryl difluoride EC No: 220-281-5 CAS No: 2699-79-8	> 994 g/kg	1 January 2009	31 December 2010	31 December 2018	8	Member States shall ensure that authorisations are subject to the following conditions: (1) the product may only be sold to and used by professionals trained to use it; (2) appropriate risk mitigation measures are included for operators and bystanders; (3) concentrations of sulfuryl fluoride in remote tropospheric air are monitored. Member States shall also ensure that reports of the monitoring referred to in point (3) are transmitted by authorisation holders directly to the Commission every fifth year starting from 1 January 2009 .
[F4			994 g/kg	1 July 2011	30 June 2013	30 June 2021	18	Member States shall ensure that authorisations are subject to the following conditions: (1) Products shall only be sold to and used by professionals trained to use them. (2) Appropriate measures to protect fumigators and bystanders during fumigation and venting of treated buildings or other enclosures must be taken. (3) Labels and/or safety-data sheets of products shall indicate that, prior to fumigation of any enclosure, all food items must be removed. (4) Concentrations of sulfuryl fluoride in remote tropospheric air are monitored. (5) Member States shall also ensure that reports of the monitoring referred to in point (4) are transmitted by authorisation holders directly to the Commission every fifth year, starting at the latest five years after the authorisation. The limit of detection for the analysis shall be at least 0,5 ppt (equivalent to 2,1 ng sulfuryl fluoride/m 3 of tropospheric air).]
[F5 2	dichlofluanid	N-(Dichlorofluoromethylthio)-N′,N′-dimethyl-N-phenylsulfamide EC No: 214-118-7 CAS No: 1085-98-9	> 96 % w/w	1 March 2009	28 February 2011	28 February 2019	8	Member States shall ensure that authorisations are subject to the following conditions: (1) Products authorised for industrial and/or professional use must be used with appropriate personal protective equipment. (2) In view of the risks identified for the soil compartment appropriate risk mitigation measures must be taken to protect that compartment. (3) Labels and/or safety-data sheets of products authorised for industrial use indicate that freshly treated timber must be stored after treatment on impermeable hard standing to prevent direct losses to soil and that any losses must be collected for re-use or disposal.]
[F6 3	clothianidin	(E)-1-(2-Chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine EC No: 433-460-1 CAS No: 210880-92-5	950 g/kg	1 February 2010	31 January 2012	31 January 2020	8	When assessing, in accordance with Article 5 and Annex VI, the application for authorisation of a product, Member States shall assess those use/exposure scenarios and/or populations that have not been representatively addressed in the Community level risk assessment and that may be exposed to the product. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: In view of the risk identified for the soil, surface water and groundwater compartments, products cannot be authorised for the treatment of wood that will be used outdoors unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. In particular, labels and/or safety-data sheets of products authorised for industrial use indicate that freshly treated timber must be stored after treatment on impermeable hard standing to prevent direct losses to soil and that any losses must be collected for reuse or disposal.]
[F7 4	Difethialone	3-[3-(4′-bromo[1,1′biphenyl]-4-yl)-1,2,3,4-tetrahydronaphth-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one EC No: n/a CAS No: 104653-34-1	976 g/kg	1 November 2009	31 October 2011	31 October 2014	14	In view of the fact that the active substance characteristics render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, the active substance is to be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in the products shall not exceed 0,0025 % w/w and only ready-for-use baits shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Products shall not be used as tracking powder. (4) Primary as well as secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F8 5	etofenprox	3-phenoxybenzyl-2-(4-ethoxyphenyl)-2-methylpropylether EC No: 407-980-2 CAS No: 80844-07-1	970 g/kg	1 February 2010	31 January 2012	31 January 2020	8	When assessing, in accordance with Article 5 and Annex VI, the application for authorisation of a product, Member States shall access those use and/or exposure scenarios and/or populations that have not been representatively addressed in the Community level risk assessment and that may be exposed to the product. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: In view of the risk identified for workers, products cannot be used year round unless dermal absorption data is provided to demonstrate that there are no unacceptable risks from chronic exposure. In addition, products intended for industrial use must be used with appropriate personal protective equipment.]
[F9 6	tebuconazole	1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol EC No: 403-640-2 CAS No: 107534-96-3	950 g/kg	1 April 2010	31 March 2012	31 March 2020	8	Member States shall ensure that authorisations are subject to the following conditions: In view of the risks identified for the soil and aquatic compartments appropriate risk mitigation measures must be taken to protect those compartments. In particular, labels and/or safety data sheets of products authorised for industrial use indicate that freshly treated timber must be stored after treatment under shelter or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal. In addition, products cannot be authorised for the in situ treatment of wood outdoors or for wood that will be in continuous contact with water unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.]
[F10 7	carbon dioxide	carbon dioxide EC No: 204-696-9 CAS No: 124-38-9	990 ml/l	1 November 2009	31 October 2011	31 October 2019	14	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels.]
[F11			990 ml/l	1 November 2012	31 October 2014	31 October 2022	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to compartments and populations that have not been representatively addressed in the European level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Member States shall ensure that authorisations are subject to the following conditions: (1) Product shall only be sold to and used by professionals trained to use them. (2) Appropriate measures to protect operators shall be taken to ensure minimum risk, including the availability of personal protective equipment if necessary. (3) Appropriate measures shall be taken to protect bystanders, such as exclusion from the treatment area during fumigation.]
[F12 8	propiconazole	1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole EC No: 262-104-4 CAS No: 60207-90-1	930 g/kg	1 April 2010	31 March 2012	31 March 2020	8	Member States shall ensure that authorisations are subject to the following conditions: In view of the assumptions made during the risk assessment, products authorised for industrial and/or professional use, must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by other means. In view of the risks identified for the soil and aquatic compartments appropriate risk mitigation measures must be taken to protect those compartments. In particular, labels and/or safety data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal. In addition, products cannot be authorised for the in situ treatment of wood outdoors or for wood that will be exposed to weathering unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.]
[F13 9	Difenacoum	3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin EC No: 259-978-4 CAS No: 56073-07-5	960 g/kg	1 April 2010	31 March 2012	31 March 2015	14	In view of the fact that the active substance characteristics render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, the active substance is to be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in the products shall not exceed 75 mg/kg and only ready-for-use products shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Products shall not be used as tracking powder. (4) Primary as well as secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F14 10	K-HDO	Cyclohexylhydroxydiazene 1-oxide, potassium salt EC No: n/a CAS No: 66603-10-9 (This entry also covers the hydrated forms of K-HDO)	977 g/kg	1 July 2010	30 June 2012	30 June 2020	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. Member States shall ensure that authorisations are subject to the following conditions: (1) in view of the possible risks for the environment and workers, products shall not be used in other systems than industrial, fully automated and closed ones unless the application for product authorisation demonstrates that risks can be reduced to acceptable levels in accordance with Article 5 and Annex VI; (2) in view of the assumptions made during the risk assessment, products must be used with appropriate personal protective equipment, unless the application for product authorisation demonstrates that risks to users can be reduced to acceptable levels by other means; (3) in view of the risk identified for infants, products shall not be used for the treatment of wood that may enter in direct contact with infants.]
[F15 11	IPBC	3-iodo-2-propynyl butylcarbamate EC No: 259-627-5 CAS No: 55406-53-6	980 g/kg	1 July 2010	30 June 2012	30 June 2020	8	Member States shall ensure that authorisations are subject to the following conditions: In view of the assumptions made during the risk assessment, products authorised for industrial and/or professional use, must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by other means. In view of the risks identified for the soil and aquatic compartments appropriate risk mitigation measures must be taken to protect those compartments. In particular, labels and/or safety data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter or on impermeable hardstanding to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal.]
[F16 12	Chlorophacinone	Chlorophacinone EC No: 223-003-0 CAS No: 3691-35-8	978 g/kg	1 July 2011	30 June 2013	30 June 2016	14	In view of the identified risks for non-target animals, the active substance shall be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in products other than tracking powder shall not exceed 50 mg/kg and only ready-for use products shall be authorised. (2) Products to be used as tracking powder shall only be placed on the market for use by trained professionals. (3) Products shall contain an aversive agent and, where appropriate, a dye. (4) Primary as well as secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F17 13	Thiabendazole	2-thiazol-4-yl-1H-benzoimidazole EC No: 205-725-8 CAS No: 148-79-8	985 g/kg	1 July 2010	30 June 2012	30 June 2020	8	Member States shall ensure that authorisations are subject to the following conditions: in view of the assumptions made during the risk assessment, products authorised for industrial and/or professional use, with respect to the double-vacuum and dipping application tasks, must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by others means. In view of the risks identified for the soil and aquatic compartments appropriate risk mitigation measures must be taken to protect those compartments. In particular, labels and/or safety data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal. Products shall not be authorised for the in situ treatment of wood outdoors or for wood that will be exposed to weathering, unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.]
[F18 14	thiamethoxam	thiamethoxam EC No: 428-650-4 CAS No: 153719-23-4	980 g/kg	1 July 2010	30 June 2012	30 June 2020	8	Member States shall ensure that authorisations are subject to the following conditions: In view of the assumptions made during the risk assessment, products authorised for industrial and/or professional use must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by other means. In view of the risks identified for the soil and aquatic compartments appropriate risk mitigation measures must be taken to protect those compartments. In particular, labels and/or safety data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal. Products shall not be authorised for the in situ treatment of wood outdoors or for wood that will be exposed to weathering, unless data have been submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.]
[F19 15	alphachloralose	(R)-1,2-O-(2.2,2-Trichloroethylidene)-α-D-glucofuranose EC No: 240-016-7 CAS No: 15879-93-3	825 g/kg	1 July 2011	30 June 2013	30 June 2021	14	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. In particular, products cannot be authorised for outdoor use unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in the products shall not exceed 40 g/kg. (2) Products shall contain an aversive agent and a dye. (3) Only products for use in tamper resistant and securely closed bait boxes shall be authorised.]
[F20 16	brodifacoum	3-[3-(4'-bromobiphenyl-4-yl)-1,2,3,4-tetrahydro-1-napthyl]-4-hydroxycoumarin EC No: 259-980-5 CAS No: 56073-10-0	950 g/kg	1 February 2012	31 January 2014	31 January 2017	14	In view of the fact that the active substance characteristics render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, the active substance is to be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in the products shall not exceed 50 mg/kg and only ready-for-use products shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Products shall not be used as tracking powder. (4) Primary as well as secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F21 17	bromadiolone	3-[3-(4’-Bromo[1,1’-biphenyl]-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-1-benzopyran-2-one EC No: 249-205-9 CAS No: 28772-56-7	969 g/kg	1 July 2011	30 June 2013	30 June 2016	14	In view of the fact that the active substance characteristics render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, the active substance is to be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in the products shall not exceed 50 mg/kg and only ready-for-use products shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Products shall not be used as tracking powder. (4) Primary as well as secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F22 18	Thiacloprid	(Z)-3-(6-chloro-3-pyridylmethyl)-1,3-thiazolidin-2-ylidenecyanamide EC No: n/a CAS No: 111988-49-9	975 g/kg	1 January 2010	n/a	31 December 2019	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: (1) In view of the assumptions made during the risk assessment, products authorised for industrial and/or professional use, must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by other means. (2) In view of the risks identified for the soil and aquatic compartments appropriate risk mitigation measures must be taken to protect those compartments. In particular, labels and/or safety-data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter and/or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal. (3) Products shall not be authorised for the in situ treatment of wooden structures near water, where direct losses to the aquatic compartment cannot be prevented, or for wood that will be in contact with surface water, unless data have been submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.]
[F23 19	Indoxacarb (enantiomeric reaction mass S:R 75:25)	Reaction mass of methyl (S)- and methyl(R)-7-chloro-2.3,4a,5-tetrahydro-2-[methoxycarbonyl-(4-trifluoromethoxyphenyl) carbamoyl]indeno[1,2-e][1.3,4]oxadiazine-4a-carboxylate (This entry covers the 75:25 reaction mass of the S and R enantiomers) EC No: n/a CAS No: S-enantiomer: 173584-44-6 and R-enantiomer: 185608-75-7)	796 g/kg	1 January 2010	n/a	31 December 2019	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: Appropriate risk mitigation measures must be taken to minimise the potential exposure of humans, of non-target species and of the aquatic environment. In particular, labels and/or safety-data sheets of products authorised shall indicate that: (1) Products shall not be placed in areas accessible to infants, children and companion animals. (2) Products shall be positioned away from external drains. (3) Unused products shall be disposed of properly and not washed down the drain. For amateur uses, only ready-to-use products shall be authorised.]
[F24 20	aluminium phosphide releasing phosphine	aluminium phosphide EC No: 244-088-0 CAS No: 20859-73-8	830 g/kg	1 September 2011	31 August 2013	31 August 2021	14	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. In particular, products cannot be authorised for indoor use unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. Member States shall ensure that authorisations are subject to the following conditions: (1) Products shall only be sold to and used by specifically trained professionals. (2) In view of the risks identified for operators, appropriate risk mitigation measures must be applied. These include, amongst others, the use of appropriate personal protective equipment, the use of applicators and the presentation of the product in a form designed to reduce operator exposure to an acceptable level. (3) In view of the risks identified for terrestrial non-target species, appropriate risk reduction measures must be applied. These include, amongst others, the non-treatment of areas where other burrowing mammals than the target species are present.]
[F25			830 g/kg	1 February 2012	31 January 2014	31 January 2022	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to compartments and populations that have not been representatively addressed in the Union level risk assessment. In particular, where relevant, Member States shall assess outdoor use. When granting product authorisation, Member States shall ensure that adequate residue trials are provided to allow consumer risk assessment and that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Member States shall ensure that authorisations are subject to the following conditions: (1) Products shall only be supplied to and used by specifically trained professionals in the form of ready-for-use products. (2) In view of the risks identified for operators, appropriate risk mitigation measures must be applied. Those include, amongst others, the use of appropriate personal and respiratory protective equipment, the use of applicators and the presentation of the product in a form designed to reduce the exposure of operators to an acceptable level. For indoor use, those include also the protection of operators and workers during fumigation, the protection of workers at re-entry (after fumigation period) and the protection of bystanders against leaking of gas. (3) For products containing aluminium phosphide that may lead to residues in food or feed, labels and/or safety data sheets for authorised products must contain instructions for use, such as the adherence to waiting periods, which ensure compliance with the provisions laid down in Article 18 of Regulation (EC) No 396/2005 of the European Parliament and of the Council ( OJ L 70, 16.3.2005, p. 1 ).]
[F26 21	fenpropimorph	(+/-)-cis-4-[3-(p-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine EC No: 266-719-9 CAS No: 67564-91-4	930 g/kg	1 July 2011	30 June 2013	30 June 2021	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: (1) In view of the assumptions made during the risk assessment, products authorised for industrial use must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial users can be reduced to an acceptable level by other means. (2) In view of the risks identified for the soil and aquatic compartments, appropriate risk mitigation measures must be taken to protect those compartments. In particular, labels and/or safety-data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter and/or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal.]
[F27 22	boric acid	boric acid EC No: 233-139-2 CAS No: 10043-35-3	990 g/kg	1 September 2011	31 August 2013	31 August 2021	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: (1) Products authorised for industrial and professional use must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by other means. (2) In view of the risks identified for the soil and aquatic compartments, products shall not be authorised for the in situ treatment of wood outdoors or for wood that will be exposed to weathering, unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. In particular, labels and/or safety-data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter and/or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal.]
[F28 23	boric oxide	Diboron trioxide EC No: 215-125-8 CAS No: 1303-86-2	975 g/kg	1 September 2011	31 August 2013	31 August 2021	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: (1) Products authorised for industrial and professional use must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by other means. (2) In view of the risks identified for the soil and aquatic compartments, products shall not be authorised for the in situ treatment of wood outdoors or for wood that will be exposed to weathering, unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. In particular, labels and/or safety-data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter and/or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal.]
[F29 24	disodium tetraborate	disodium tetraborate EC No: 215-540-4 CAS No (anhydrous): 1330-43-4 CAS No (pentahydrate): 12267-73-1 CAS No (decahydrate): 1303-96-4	990 g/kg	1 September 2011	31 August 2013	31 August 2021	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: (1) Products authorised for industrial and professional use must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by other means. (2) In view of the risks identified for the soil and aquatic compartments, products shall not be authorised for the in situ treatment of wood outdoors or for wood that will be exposed to weathering, unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. In particular, labels and/or safety-data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter and/or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal.]
[F30 25	disodium octaborate tetrahydrate	disodium octaborate tetrahydrate EC No: 234-541-0 CAS No: 12280-03-4	975 g/kg	1 September 2011	31 August 2013	31 August 2021	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: (1) Products authorised for industrial and professional use must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by other means. (2) In view of the risks identified for the soil and aquatic compartments, products shall not be authorised for the in situ treatment of wood outdoors or for wood that will be exposed to weathering, unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. In particular, labels and/or safety-data sheets of products authorised for industrial use shall indicate that freshly treated timber must be stored after treatment under shelter and/or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal.]
[F31 26	Magnesium phosphide releasing phosphine	Trimagnesium diphosphide EC No: 235-023-7 CAS No: 12057-74-8	880 g/kg	1 February 2012	31 January 2014	31 January 2022	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to compartments and populations that have not been representatively addressed in the Union level risk assessment. In particular, where relevant, Member States shall assess outdoor use. When granting product authorisation, Member States shall ensure that adequate residue trials are provided to allow consumer risk assessment and that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Member States shall ensure that authorisations are subject to the following conditions: (1) Products shall only be supplied to and used by specifically trained professionals in the form of ready-for-use products. (2) In view of the risks identified for operators, appropriate risk mitigation measures must be applied. Those include, amongst others, the use of appropriate personal and respiratory protective equipment, the use of applicators and the presentation of the product in a form designed to reduce the exposure of operators to an acceptable level. For indoor use, those include also the protection of operators and workers during fumigation, the protection of workers at re-entry (after fumigation period) and the protection of bystanders against leaking of gas. (3) For products containing magnesium phosphide that may lead to residues in food or feed, labels and/or safety data sheets for authorised products must contain instructions for use, such as the adherence to waiting periods, which ensure compliance with the provisions laid down in Article 18 of Regulation (EC) No 396/2005 of the European Parliament and of the Council ( OJ L 70, 16.3.2005, p. 1 ).]
[F32 27	Nitrogen	Nitrogen EC No: 231-783-9 CAS No: 7727-37-9	999 g/kg	1 September 2011	31 August 2013	31 August 2021	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Community level risk assessment. When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks. Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels. Member States shall ensure that authorisations are subject to the following conditions: (1) Products may only be sold to and used by professionals trained to use them. (2) Safe working practices and safe systems of work must be in place to ensure minimum risk, including the availability of personal protective equipment if necessary.]
[F33 28	Coumatetralyl	Coumatetralyl EC No: 227-424-0 CAS No: 5836-29-3	980 g/kg	1 July 2011	30 June 2013	30 June 2016	14	In view of the identified risks for non-target animals, the active substance shall be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in products other than tracking powder shall not exceed 375 mg/kg and only ready-for use products shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Primary as well as secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F34 29	tolylfluanid	Dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide EC No: 211-986-9 CAS No: 731-27-1	960 g/kg	1 October 2011	30 September 2013	30 September 2021	8	Products shall not be authorised for the in situ treatment of wood outdoors or for wood that will be exposed to weathering. Member States shall ensure that authorisations are subject to the following conditions: (1) In view of the assumptions made during the risk assessment, products authorised for industrial or professional use must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial or professional users can be reduced to an acceptable level by other means. (2) In view of the risks identified for the soil and aquatic compartments, appropriate risk mitigation measures must be taken to protect those compartments. In particular, labels and/or safety-data sheets of products authorised for industrial or professional use shall indicate that freshly treated timber must be stored after treatment under shelter and/or on impermeable hard standing to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal.]
[F35 30	Acrolein	Acrylaldehyde EC No: 203-453-4 CAS No: 107-02-8	913 g/kg	1 September 2010	Not applicable	31 August 2020	12	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, where relevant for the particular product, the populations that may be exposed to the product and the use or exposure scenarios that have not been representatively addressed at the Union level risk assessment. Member States shall ensure that authorisations are subject to the following conditions: (1) Waste waters containing acrolein shall be monitored prior to discharge, unless it can be demonstrated that risks for the environment can be reduced by other means. Where necessary in view of the risks to marine environment, waste waters shall be held in suitable tanks or reservoirs or appropriately treated before discharge. (2) Products authorised for industrial and/or professional use shall be used with appropriate personal protective equipment, and safe operational procedures shall be established, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by others means.]
[F36 31	Flocoumafen	4-hydroxy-3-[(1 RS ,3 RS ;1 RS ,3 RS )-1,2,3,4-tetrahydro-3-[4-(4-trifluoromethylbenzyloxy)phenyl]-1-naphthyl]coumarin EC No 421-960-0 CAS No 90035-08-8	955 g/kg	1 October 2011	30 September 2013	30 September 2016	14	In view of the fact that the active substance characteristics render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, the active substance is to be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in products shall not exceed 50 mg/kg and only ready-for-use products shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Products shall not be used as tracking powder. (4) Primary as well as secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. Those include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F37 32	Warfarin	(RS)-4-hydroxy-3-(3-oxo-1-phenylbutyl)coumarin EC No: 201-377-6 CAS No: 81-81-2	990 g/kg	1 February 2012	31 January 2014	31 January 2017	14	The active substance shall be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) the nominal concentration of the active substance shall not exceed 790 mg/kg and only ready-for-use products shall be authorised; (2) products shall contain an aversive agent and, where appropriate, a dye; (3) primary and secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the possibility of restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F38 33	Warfarin sodium	Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate EC No: 204-929-4 CAS No: 129-06-6	910 g/kg	1 February 2012	31 January 2014	31 January 2017	14	The active substance shall be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) the nominal concentration of the active substance shall not exceed 790 mg/kg and only ready-for-use products shall be authorised; (2) products shall contain an aversive agent and, where appropriate, a dye; (3) primary and secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the possibility of restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.]
[F39 34	Dazomet	Tetrahydro-3,5-dimethyl-1,3,5-thiadiazine-2-thione EC No: 208-576-7 CAS No: 533-74-4	960 g/kg	1 August 2012	31 July 2014	31 July 2022	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to compartments and populations that have not been representatively addressed in the EU level risk assessment. In particular, where relevant, Member States shall assess any other use than professional use outdoors for the remedial treatment of wooden poles by insertion of granules. Member States shall ensure that authorisations are subject to the following condition: Products authorised for industrial and/or professional use shall be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial and/or professional users can be reduced to an acceptable level by others means.]
[F40 35	N,N-diethyl-meta-toluamide	N,N-diethyl-m-toluamide EC No: 205-149-7 CAS No: 134-62-3	970 g/kg	1 August 2012	31 July 2014	31 July 2022	19	Member States shall ensure that authorisations are subject to the following conditions: (1) primary exposure of humans shall be minimized by considering and applying appropriate risk mitigation measures, including, where applicable, instructions for the amount and frequency of application of the product on human skin; (2) labels on products intended for application on human skin, hair or clothing shall indicate that the product is intended only for restricted use on children between two and twelve years old, and that it is not intended for use on children less than two years old, unless it can be demonstrated in the application for product authorisation that the product will meet the requirements of Article 5 and Annex VI without such measures; (3) products must contain deterrents for ingestion.]
[F41 36	Metofluthrin	RTZ isomer: 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl-(1R,3R)-2,2-dimethyl-3-(Z)-(prop-1-enyl)cyclopropanecarboxylate EC No: n.a. CAS No: 240494-71-7 Sum of all isomers: 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (EZ)-(1RS,3RS;1SR,3SR)-2,2-dimethyl-3-prop-1-enylcyclopropanecarboxylate EC No: n.a. CAS No: 240494-70-6	The active substance shall comply with both the following minimum purities: RTZ isomer: 754 g/kg Sum of all isomers: 930 g/kg	1 May 2011	Not applicable	30 April 2021	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to compartments and populations that have not been representatively addressed in the European level risk assessment.]
[F42 37	Spinosad	EC No: 434-300-1 CAS No: 168316-95-8 Spinosad is a mixture of 50-95 % spinosyn A and 5-50 % spinosyn D. Spinosyn A (2R,3aS,5aR,5bS,9S,13S,14R,16aS,16bR)-2-[(6-deoxy-2,3,4-tri-O-methyl-α-L-mannopyranosyl)oxy]-13-[[(2R,5S,6R)-5-(dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl]oxy]-9-ethyl-2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-14-methyl-1H-as-indaceno[3,2-d]oxacyclododecin-7,15-dione CAS No: 131929-60-7 Spinosyn D (2S,3aR,5aS,5bS,9S,13S,14R,16aS,16bS)-2-[(6-deoxy-2,3,4-tri-O-methyl-α-L-mannopyranosyl)oxy]-13-[[(2R,5S,6R)-5-(dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl]oxy]-9-ethyl-2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-4,14-dimethyl-1H-as-indaceno[3,2-d]oxacyclododecin-7,15-dione CAS No: 131929-63-0	850 g/kg	1 November 2012	31 October 2014	31 October 2022	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to compartments and populations that have not been representatively addressed in the EU level risk assessment. Member States shall ensure that authorisations are subject to the following conditions: Authorisations shall be subject to appropriate risk mitigation measures. In particular, products authorised for professional use by spraying shall be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to professional users can be reduced to an acceptable level by others means. For products containing spinosad that may lead to residues in food or feed, Member States shall verify the need to set new and/or amended existing maximum residue levels (MRLs) according to Regulation (EC) No 470/2009 and/or Regulation (EC) No 396/2005, and take any appropriate risk mitigation measures ensuring that the applicable MRLs are not exceeded.]
[F43 38	Bifenthrin	IUPAC name: 2-methylbiphenyl-3-ylmethyl (1RS)-cis-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropanecarboxylate EC No: n.a. CAS No: 82657-04-3	911 g/kg	1 February 2013	31 January 2015	31 January 2023	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to environmental compartments and populations that have not been representatively addressed in the Union level risk assessment. Member States shall ensure that authorisations are subject to the following conditions: Products shall be authorised only for industrial or professional use, unless it is demonstrated in the application for product authorisation that risks to non-professional users can be reduced to acceptable levels in accordance with Article 5 and Annex VI. Products authorised for industrial or professional use must be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to industrial or professional users can be reduced to an acceptable level by other means. Appropriate risk mitigation measures shall be taken to protect the soil and aquatic compartments. In particular, labels and, where provided, safety data sheets of products authorised shall indicate that freshly treated timber shall be stored after treatment under shelter or on impermeable hardstanding, or both, to prevent direct losses to soil or water, and that any losses from the application of the product shall be collected for reuse or disposal. Products shall not be authorised for the in situ treatment of wood outdoors, or for treatment of wood that will be either continually exposed to the weather or protected from the weather but subject to frequent wetting, unless data have been submitted demonstrating that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.]
[F44 39	(Z,E)-tetradeca-9,12-dienyl acetate	(9Z,12E)-Tetradeca-9,12-dien-1-yl acetate EC No: n.a. CAS No: 30507-70-1	977 g/kg	1 February 2013	31 January 2015	31 January 2023	19	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to environmental compartments and populations that have not been representatively addressed in Union level risk assessment. Member States shall ensure that authorisations are subject to the following condition: Labels for biocidal products containing (Z,E)-tetradeca-9,12-dienyl acetate shall indicate that those products shall not be used in spaces where un-packaged food or feed is kept.]
[F45 40	Fenoxycarb	IUPAC name: Ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate EC No: 276-696-7 CAS No: 72490-01-8	960 g/kg	1 February 2013	31 January 2015	31 January 2023	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to environmental compartments and populations that have not been representatively addressed in the Union level risk assessment. Member States shall ensure that authorisations are subject to the following conditions: Appropriate risk mitigation measures shall be taken to protect the soil and aquatic compartments. In particular, labels and, where provided, safety data sheets of products authorised shall indicate that freshly treated timber shall be stored after treatment under shelter or on impermeable hardstanding under roof, or both, to prevent direct losses to soil or water, and that any losses from the application of the product shall be collected for reuse or disposal. Products shall not be authorised for treatment of wood that will be used in outdoor constructions near or above water, unless data is submitted demonstrating that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.]
[F46 41	Nonanoic acid, Pelargonic acid	IUPAC name: Nonanoic acid EC No: 203-931-2 CAS No: 112-05-0	896 g/kg	1 February 2013	31 January 2015	31 January 2023	19	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to environmental compartments and populations that have not been representatively addressed in Union level risk assessment.]
[F47 42	imidacloprid	(2E)-1-[(6-chloropyridin-3-yl)methyl]-N-nitroimidazolidin-2-imine EC No: 428-040-8 CAS No: 138261-41-3	970 g/kg	1 July 2013	30 June 2015	30 June 2023	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment. Products shall not be authorised for uses in animal housings where emission to a sewage treatment plant or direct emission to surface water cannot be prevented, unless data is submitted demonstrating that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. Authorisations shall be subject to appropriate risk mitigation measures. In particular, appropriate risk mitigation measures shall be taken to minimise the potential exposure of infants and children. For products containing imidacloprid that may lead to residues in food or feed, Member States shall verify the need to set new or amended existing maximum residue levels (MRLs) according to Regulation (EC) No 470/2009 or Regulation (EC) No 396/2005, and take any appropriate risk mitigation measures ensuring that the applicable MRLs are not exceeded.]
[F48 43	Abamectin	Abamectin is a mixture of avermectin B 1a and avermectin B 1b Abamectin: IUPAC name: n.a. EC No: n.a. CAS No: 71751-41-2 Avermectin B 1a : IUPAC name: (10E,14E,16E,22Z)-(1R,4S,5'S,6S,6'R,8R,12S,13S,20R,21R,24S)-6'-[(S)-secbutyl]-21,24-dihydroxy-5',11,13,22-tetramethyl-2-oxo-3,7,19-trioxatetracyclo[15.6.1.1 4,8 .0 20,24 ]pentacosa-10,14,16,22-tetraene-6-spiro-2'-(5',6'-dihydro-2'H-pyran)-12-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabinohexopyranoside EC No: 265-610-3 CAS No: 65195-55-3 Avermectin B 1b : IUPAC name: (10E,14E,16E,22Z)-(1R,4S,5'S,6S,6'R,8R,12S,13S,20R,21R,24S)-21,24-dihydroxy-6'-isopropyl-5',11,13,22-tetramethyl-2-oxo-3,7,19-trioxatetracyclo[15.6.1.1 4,8 .0 20,24 ]pentacosa-10,14,16,22-tetraene-6-spiro-2'-(5',6'-dihydro-2'H-pyran)-12-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabinohexopyranoside EC No: 265-611-9 CAS No: 65195-56-4	The active substance shall comply with all the following purities: Abamectin: minimum 900 g/kg Avermectin B 1a : minimum 830 g/kg Avermectin B 1b : maximum 80 g/kg	1 July 2013	30 June 2015	30 June 2023	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment. Products applied in such a way that emission to a sewage treatment plant cannot be prevented shall not be authorised for those application rates for which the Union level risk assessment showed unacceptable risks, unless data are submitted demonstrating that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. Authorisations shall be subject to appropriate risk mitigation measures. In particular, appropriate risk mitigation measures shall be taken to minimise the potential exposure of infants and children.]
[F49 44	4,5-Dichloro-2-octyl-2H-isothiazol-3-one	4,5-Dichloro-2-octylisothiazol-3(2 H )-one EC No: 264-843-8 CAS No: 64359-81-5	950 g/kg	1 July 2013	30 June 2015	30 June 2023	8	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, when relevant for the particular product, those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment. Products shall not be authorised for treatment of wood that will be continually exposed to the weather, protected from the weather but subject to frequent wetting or in contact with fresh water, unless data have been submitted demonstrating that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. Member States shall ensure that authorisations are subject to the following conditions: (1) for products authorised for industrial or professional use, safe operational procedures shall be established, and products shall be used with appropriate personal protective equipment unless it can be demonstrated in the application for product authorisation that risks to industrial or professional users can be reduced to an acceptable level by other means; (2) labels and, where provided, safety data sheets of products authorised shall indicate that freshly treated timber shall be stored after treatment under shelter or on impermeable hard standing under roof, or both, to prevent direct losses to soil or water, and that any losses from the application of the product shall be collected for reuse or disposal.]
[F3 45	Creosote	Creosote EC No: 232-287-5 CAS No: 8001-58-9	Grade B or Grade C creosote as specified in European Standard EN 13991:2003	1 May 2013	30 April 2015	30 April 2018	8	Biocidal products containing creosote may only be authorised for uses where the authorising Member State, based on an analysis regarding the technical and economic feasibility of substitution which it shall request from the applicant, as well as on any other information available to it, concludes that no appropriate alternatives are available. Those Member States authorising such products in their territory shall no later than 31 July 2016 submit a report to the Commission justifying their conclusion that there are no appropriate alternatives and indicating how the development of alternatives is promoted. The Commission will make these reports publicly available. The active substance is to be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) before its inclusion in this Annex is renewed. When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, where relevant for the particular product, those uses or exposure scenarios and those risks to environmental compartments and populations that have not been representatively addressed at the Union level risk assessment. Member States shall ensure that authorisations are subject to the following conditions: (1) Creosote may only be used under the conditions mentioned in point 2 of the second column of entry No 31 in Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC b . (2) Creosote shall not be used for the treatment of wood intended for those uses referred to in point 3 of the second column of entry No 31 in Annex XVII to Regulation (EC) No 1907/2006. (3) Appropriate risk mitigation measures shall be taken to protect workers, including down-stream users, from exposure during treatment and handling of treated wood in compliance with Regulation (EC) No 1907/2006 and Directive 2004/37/EC of the European Parliament and of the Council of 29 April 2004 on the protection of workers from the risks related to exposure to carcinogens or mutagens at work (Sixth individual Directive within the meaning of Article 16(1) of Council Directive 89/391/EEC) c . (4) Appropriate risk mitigation measures shall be taken to protect the soil and aquatic compartments. In particular, labels and, where provided, safety data sheets of products authorised shall indicate that freshly treated timber must be stored after treatment under shelter or on impermeable hard standing, or both, to prevent direct losses to soil or water and that any losses must be collected for reuse or disposal.]
[F50 46	Bacillus thuringiensis subsp. israelensis Serotype H14, Strain AM65-52	Not applicable	No relevant impurities	1 October 2013	30 September 2015	30 September 2023	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, where relevant for the particular product, those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment. Products authorised for professional use shall be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to professional users can be reduced to an acceptable level by other means. For products containing Bacillus thuringiensis subsp. israelensis Serotype H14, Strain AM65-52 that may lead to residues in food or feed, Member States shall verify the need to set new or to amend existing maximum residue levels (MRLs) according to Regulation (EC) No 470/2009 or Regulation (EC) No 396/2005, and take any appropriate risk mitigation measures ensuring that the applicable MRLs are not exceeded.]
[F51 47	fipronil	(±)-5-amino-1-(2,6-dichloro-α,α,α,-trifluoro-p-tolyl)-4-trifluoromethylsulfinylpyrazole-3-carbonitrile (1:1) EC No: 424-610-5 CAS No: 120068-37-3	950 g/kg	1 October 2013	30 September 2015	30 September 2023	18	Only professional use indoors by application in locations normally inaccessible after application to man and domestic animals has been addressed in the Union level risk assessment. When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, where relevant for the particular product, those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment.]
[F52 48	lambda-cyhalothrin	Reaction mass of (R)-α-cyano-3-phenoxybenzyl (1S,3S)-3-[(Z)-2-chloro-3,3,3-trifluoropropenyl]-2,2-dimethylcyclopropanecarboxylate and (S)-α-cyano-3-phenoxybenzyl (1R,3R)-3-[(Z)-2-chloro-3,3,3-trifluoropropenyl]-2,2-dimethylcyclopropanecarboxylate (1:1) CAS-No: 91465-08-6 EC No: 415-130-7	900 g/kg	1 October 2013	30 September 2015	30 September 2023	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, where relevant for the particular product, those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment. Products applied in such a way that emission to a sewage treatment plant cannot be prevented shall not be authorised, unless data are submitted demonstrating that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures. Products authorised for professional use shall be used with appropriate personal protective equipment, unless it can be demonstrated in the application for product authorisation that risks to professional users can be reduced to an acceptable level by other means. For products containing lambda-cyhalothrin that may lead to residues in food or feed, Member States shall verify the need to set new or to amend existing maximum residue levels (MRLs) according to Regulation (EC) No 470/2009 or Regulation (EC) No 396/2005, and take any appropriate risk mitigation measures ensuring that the applicable MRLs are not exceeded.]
[F53 49	deltamethrin	(S)-α-cyano-3-phenoxybenzyl (1R,3R)-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylate CAS-No: 52918-63-5 EC No: 258-256-6	985 g/kg	1 October 2013	30 September 2015	30 September 2023	18	When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, where relevant for the particular product, those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment. Products shall not be authorised for indoor treatments resulting in sewage treatment plant emissions of the scale for which the Union level risk assessment showed unacceptable risks, unless data are submitted demonstrating that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.]

Textual Amendments

F1 Inserted by Commission Directive 2006/140/EC of 20 December 2006 amending Directive 98/8/EC of the European Parliament and of the Council to include sulfuryl fluoride as an active substance in Annex I thereto (Text with EEA relevance).

F2 Substituted by Commission Directive 2007/69/EC of 29 November 2007 amending Directive 98/8/EC of the European Parliament and of the Council to include difethialone as an active substance in Annex I thereto (Text with EEA relevance).

F3 Inserted by Commission Directive 2011/71/EU of 26 July 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include creosote as an active substance in Annex I thereto (Text with EEA relevance).

F4 Inserted by Commission Directive 2009/84/EC of 28 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include sulfuryl fluoride as an active substance in Annex I thereto (Text with EEA relevance).

F5 Inserted by Commission Directive 2007/20/EC of 3 April 2007 amending Directive 98/8/EC of the European Parliament and of the Council to include dichlofluanid as an active substance in Annex I thereto (Text with EEA relevance).

F6 Inserted by Commission Directive 2008/15/EC of 15 February 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include clothianidin as an active substance in Annex I thereto (Text with EEA relevance).

F7 Inserted by Commission Directive 2007/69/EC of 29 November 2007 amending Directive 98/8/EC of the European Parliament and of the Council to include difethialone as an active substance in Annex I thereto (Text with EEA relevance).

F8 Inserted by Commission Directive 2008/16/EC of 15 February 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include etofenprox as an active substance in Annex I thereto (Text with EEA relevance).

F9 Inserted by Commission Directive 2008/86/EC of 5 September 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include tebuconazole as an active substance in Annex I thereto (Text with EEA relevance).

F10 Inserted by Commission Directive 2008/75/EC of 24 July 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include carbon dioxide as an active substance in Annex I thereto (Text with EEA relevance).

F11 Inserted by Commission Directive 2010/74/EU of 9 November 2010 amending Directive 98/8/EC of the European Parliament and of the Council to extend the inclusion in Annex I thereto of the active substance carbon dioxide to product type 18 (Text with EEA relevance).

F12 Inserted by Commission Directive 2008/78/EC of 25 July 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include propiconazole as an active substance in Annex I thereto (Text with EEA relevance).

F13 Inserted by Commission Directive 2008/81/EC of 29 July 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include difenacoum as an active substance in Annex I thereto (Text with EEA relevance).

F14 Inserted by Commission Directive 2008/80/EC of 28 July 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include cyclohexylhydroxydiazene 1-oxide, potassium salt (K-HDO) as an active substance in Annex I thereto (Text with EEA relevance).

F15 Inserted by Commission Directive 2008/79/EC of 28 July 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include IPBC as an active substance in Annex I thereto (Text with EEA relevance).

F16 Inserted by Commission Directive 2009/99/EC of 4 August 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include chlorophacinone as an active substance in Annex I thereto (Text with EEA relevance).

F17 Inserted by Commission Directive 2008/85/EC of 5 September 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include thiabendazole as an active substance in Annex I thereto (Text with EEA relevance).

F18 Inserted by Commission Directive 2008/77/EC of 25 July 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include thiamethoxam as an active substance in Annex I thereto (Text with EEA relevance).

F19 Inserted by Commission Directive 2009/93/EC of 31 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include alphachloralose as an active substance in Annex I thereto (Text with EEA relevance).

F20 Inserted by Commission Directive 2010/10/EU of 9 February 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include brodifacoum as an active substance in Annex I thereto (Text with EEA relevance).

F21 Inserted by Commission Directive 2009/92/EC of 31 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include bromadiolone as an active substance in Annex I thereto (Text with EEA relevance).

F22 Inserted by Commission Directive 2009/88/EC of 30 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include thiacloprid as an active substance in Annex I thereto (Text with EEA relevance).

F23 Inserted by Commission Directive 2009/87/EC of 29 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include indoxacarb as an active substance in Annex I thereto (Text with EEA relevance).

F24 Inserted by Commission Directive 2009/95/EC of 31 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include aluminium phosphide releasing phosphine as an active substance in Annex I thereto (Text with EEA relevance).

F25 Inserted by Commission Directive 2010/9/EU of 9 February 2010 amending Directive 98/8/EC of the European Parliament and of the Council to extend the inclusion in Annex I thereto of the active substance aluminium phosphide releasing phosphine to product type 18 as defined in Annex V thereto (Text with EEA relevance).

F26 Inserted by Commission Directive 2009/86/EC of 29 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include fenpropimorph as an active substance in Annex I thereto (Text with EEA relevance).

F27 Inserted by Commission Directive 2009/94/EC of 31 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include boric acid as an active substance in Annex I thereto (Text with EEA relevance).

F28 Inserted by Commission Directive 2009/98/EC of 4 August 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include boric oxide as an active substance in Annex I thereto (Text with EEA relevance).

F29 Inserted by Commission Directive 2009/91/EC of 31 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include disodium tetraborate as an active substance in Annex I thereto (Text with EEA relevance).

F30 Inserted by Commission Directive 2009/96/EC of 31 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include disodium octaborate tetrahydrate as an active substance in Annex I thereto (Text with EEA relevance).

F31 Inserted by Commission Directive 2010/7/EU of 9 February 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include magnesium phosphide releasing phosphine as an active substance in Annex I thereto (Text with EEA relevance).

F32 Inserted by Commission Directive 2009/89/EC of 30 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include nitrogen as an active substance in Annex I thereto (Text with EEA relevance).

F33 Inserted by Commission Directive 2009/85/EC of 29 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include coumatetralyl as an active substance in Annex I thereto (Text with EEA relevance).

F34 Inserted by Commission Directive 2009/151/EC of 27 November 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include tolylfluanid as an active substance in Annex I thereto (Text with EEA relevance).

F35 Inserted by Commission Directive 2010/5/EU of 8 February 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include acrolein as an active substance in Annex I thereto (Text with EEA relevance).

F36 Inserted by Commission Directive 2009/150/EC of 27 November 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include flocoumafen as an active substance in Annex I thereto (Text with EEA relevance).

F37 Inserted by Commission Directive 2010/11/EU of 9 February 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include warfarin as an active substance in Annex I thereto (Text with EEA relevance).

F38 Inserted by Commission Directive 2010/8/EU of 9 February 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include warfarin sodium as an active substance in Annex I thereto (Text with EEA relevance).

F39 Inserted by Commission Directive 2010/50/EU of 10 August 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include dazomet as an active substance in Annex I thereto (Text with EEA relevance).

F40 Inserted by Commission Directive 2010/51/EU of 11 August 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include N,N-diethyl-meta-toluamide as an active substance in Annex I thereto (Text with EEA relevance).

F41 Inserted by Commission Directive 2010/71/EU of 4 November 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include metofluthrin as an active substance in Annex I thereto (Text with EEA relevance).

F42 Inserted by Commission Directive 2010/72/EU of 4 November 2010 amending Directive 98/8/EC of the European Parliament and of the Council to include spinosad as an active substance in Annex I thereto (Text with EEA relevance).

F43 Inserted by Commission Directive 2011/10/EU of 8 February 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include bifenthrin as an active substance in Annex I thereto (Text with EEA relevance).

F44 Inserted by Commission Directive 2011/11/EU of 8 February 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include (Z,E)-tetradeca-9,12-dienyl acetate as an active substance in Annexes I and IA thereto (Text with EEA relevance).

F45 Inserted by Commission Directive 2011/12/EU of 8 February 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include fenoxycarb as an active substance in Annex I thereto (Text with EEA relevance).

F46 Inserted by Commission Directive 2011/13/EU of 8 February 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include nonanoic acid as an active substance in Annex I thereto (Text with EEA relevance).

F47 Inserted by Commission Directive 2011/69/EU of 1 July 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include imidacloprid as an active substance in Annex I thereto (Text with EEA relevance).

F48 Inserted by Commission Directive 2011/67/EU of 1 July 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include abamectin as an active substance in Annex I thereto (Text with EEA relevance).

F49 Inserted by Commission Directive 2011/66/EU of 1 July 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include 4,5-Dichloro-2-octyl-2H-isothiazol-3-one as an active substance in Annex I thereto (Text with EEA relevance).

F50 Inserted by Commission Directive 2011/78/EU of 20 September 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include Bacillus thuringiensis subsp. israelensis Serotype H14, Strain AM65-52 as an active substance in Annex I thereto (Text with EEA relevance).

F51 Inserted by Commission Directive 2011/79/EU of 20 September 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include fipronil as an active substance in Annex I thereto (Text with EEA relevance).

F52 Inserted by Commission Directive 2011/80/EU of 20 September 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include lambda-cyhalothrin as an active substance in Annex I thereto (Text with EEA relevance).

F53 Inserted by Commission Directive 2011/81/EU of 20 September 2011 amending Directive 98/8/EC of the European Parliament and of the Council to include deltamethrin as an active substance in Annex I thereto (Text with EEA relevance).

ANNEX IA U.K. LIST OF ACTIVE SUBSTANCES WITH REQUIREMENTS AGREED AT COMMUNITY LEVEL FOR INCLUSION IN LOW-RISK BIOCIDAL PRODUCTS

Note: For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm]
[F54 No	Common name	IUPAC name Identification numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions
1	Carbon dioxide	Carbon dioxide EC No: 204-696-9 CAS No: 124-38-9	990 ml/l	1 November 2009	31 October 2011	31 October 2019	14	Only for use in ready-for-use gas canisters functioning together with a trapping device.
[F44 2	(Z,E)-tetradeca-9,12-dienyl acetate	(9Z,12E)-tetradeca-9,12-dien-1-yl acetate EC No: n.a. CAS No: 30507-70-1	977 g/kg	1 February 2013	31 January 2015	31 January 2023	19	Member States shall ensure that registrations are subject to the following conditions: Only for traps containing a maximum of 2 mg of (Z,E)-Tetradeca-9,12-dienyl acetate for indoor use, Labels for biocidal products containing (Z,E)-tetradeca-9,12-dienyl acetate shall indicate that those products shall only be used indoors, and shall not be used in spaces where un-packaged food or feed is kept.]

Textual Amendments

F54 Inserted by Commission Directive 2007/70/EC of 29 November 2007 amending Directive 98/8/EC of the European Parliament and of the Council to include carbon dioxide as an active substance in Annex IA thereto (Text with EEA relevance).

ANNEX IB U.K. LIST OF BASIC SUBSTANCES WITH REQUIREMENTS AGREED AT COMMUNITY LEVEL

ANNEX IIA U.K. COMMON CORE DATA SET FOR ACTIVE SUBSTANCESCHEMICAL SUBSTANCES

1. Dossiers on active substances are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

Dossier requirements U.K.

I. Applicant U.K.

II. Identity of the active substance U.K.

III. Physical and chemical properties of the active substance U.K.

IV. Methods of detection and identification U.K.

V. Effectiveness against target organisms and intended uses U.K.

VI. Toxicological profile for man and animals including metabolism U.K.

VII. Ecotoxicological profile including environmental fate and behaviour U.K.

VIII. Measures necessary to protect man, animals and the environment U.K.

IX. Classification and labelling U.K.

X. Summary and evaluation of Sections II to IX U.K.

The following data will be required to support submission on the above points.

I. APPLICANT U.K.

1.1. Name and address, etc. U.K.

1.2. Active substance manufacturer (name, address, location of plant) U.K.

II. IDENTITY U.K.

2.1. Common name proposed or accepted by ISO and synonyms U.K.

2.2. Chemical name (IUPAC nomenclature) U.K.

2.3. Manufacturer's development code number(s) U.K.

2.4. CAS and EC numbers (if available) U.K.

2.5. Molecular and structural formula (including full details of any isomeric composition), molecular mass U.K.

2.6. Method of manufacture (syntheses pathway in brief terms) of active substance U.K.

2.7. Specification of purity of the active substance in g/kg or g/l, as appropriate U.K.

2.8. Identity of impurities and additives (e.g. stabilisers), together with the structural formula and the possible range expressed as g/kg or g/l, as appropriate U.K.

2.9. The origin of the natural active substance or the precursor(s) of the active substance, e.g. an extract of a flower U.K.

2.10. Exposure data in conformity with Annex VIIA to Directive 92/32/EEC(1). U.K.

III. PHYSICAL AND CHEMICAL PROPERTIES U.K.

3.1. Melting point, boiling point, relative density (¹) U.K.

3.2. Vapour pressure (in Pa) (¹) U.K.

3.3. Appearance (physical state, colour) (²) U.K.

3.4. Absorption spectra (UV/VIS, IR, NMR), and a mass spectrum, molar extinction at relevant wavelengths, where relevant (¹) U.K.

3.5. Solubility in water including effect of pH (5 to 9) and temperature on solubility, where relevant (¹) U.K.

3.6. Partition coefficient n-octanol/water including effect of pH (5 to 9) and temperature (¹) U.K.

3.7. Thermal stability, identity of relevant breakdown products U.K.

3.8. Flammability including auto-flammability and identity of combustion products U.K.

3.9. Flash-point U.K.

3.10. Surface tension U.K.

3.11. Explosive properties U.K.

3.12. Oxidising properties U.K.

3.13. Reactivity towards container material U.K.

IV. ANALYTICAL METHODS FOR DETECTION AND IDENTIFICATION U.K.

4.1. Analytical methods for the determination of pure active substance and, where appropriate, for relevant degradation products, isomers and impurities of the active substance and additives (e.g. stabilisers) U.K.

4.2. Analytical methods including recovery rates and the limits of determination for the active substance, and for residues thereof, and where relevant in/on the following: U.K.

(a)

Soil

(b)

Air

(c)

Water: the applicant should confirm that the substance itself and any of its degradation products which fall within the definition of pesticides given for parameter 55 in Annex I to Council Directive 80/778/EEC of 15 July 1980 relating to the quality of water intended for human consumption(2) can be estimated with adequate reliability at the MAC specified in that Directive for individual pesticides

(d)

Animal and human body fluids and tissues

V. EFFECTIVENESS AGAINST TARGET ORGANISMS AND INTENDED USES U.K.

5.1. Function, e.g. fungicide, rodenticide, insecticide, bactericide U.K.

5.2. Organism(s) to be controlled and products, organisms or objects to be protected U.K.

5.3. Effects on target organisms, and likely concentration at which the active substance will be used U.K.

5.4. Mode of action (including time delay) U.K.

5.5. Field of use envisaged U.K.

5.6. User: industrial, professional, general public (non-professional) U.K.

5.7. Information on the occurrence or possible occurrence of the development of resistance and appropriate management strategies U.K.

5.8. Likely tonnage to be placed on the market per year U.K.

VI. TOXICOLOGICAL AND METABOLIC STUDIES U.K.

6.1. Acute toxicity U.K.

For studies 6.1.1 to 6.1.3, substances other than gases shall be administered via at least two routes, one of which should be the oral route. The choice of the second route will depend on the nature of the substance and the likely route of human exposure. Gases and volatile liquids should be administered by the inhalation route.

6.1.1. Oral U.K.

6.1.2. Dermal U.K.

6.1.3. Inhalation U.K.

6.1.4. Skin and eye irritation (³) U.K.

6.1.5. Skin sensitisation U.K.

6.2. Metabolism studies in mammals. Basic toxicokinetics, including a dermal absorption study U.K.

For the following studies, 6.3 (where necessary), 6.4, 6.5, 6.7 and 6.8, the required route of administration is the oral route unless it can be justified that an alternative route is more appropriate

6.3. Short-term repeated dose toxicity (28 days) U.K.

This study is not required when a sub-chronic toxicity study is available in a rodent

6.4. Subchronic toxicity 90-day study, two species, one rodent and one non-rodent U.K.

6.5. Chronic toxicity (⁴) U.K.

One rodent and one other mammalian species

6.6. Mutagenicity studies U.K.

6.6.1. In-vitro gene mutation study in bacteria U.K.

6.6.2. In-vitro cytogenicity study in mammalian cells U.K.

6.6.3. In-vitro gene mutation assay in mammalian cells U.K.

6.6.4. If positive in 6.6.1, 6.6.2 or 6.6.3, then an in-vivo mutagenicity study will be required (bone marrow assay for chromosomal damage or a micronucleus test) U.K.

6.6.5. If negative in 6.6.4 but positive in-vitro tests then undertake a second in-vivo study to examine whether mutagenicity or evidence of DNA damage can be demonstrated in tissue other than bone marrow U.K.

6.6.6. If positive in 6.6.4 then a test to assess possible germ cell effects may be required U.K.

6.7. Carcinogenicity study (⁴) U.K.

One rodent and one other mammalian species. These studies may be combined with those in 6.5

6.8. Reproductive toxicity (⁵) U.K.

6.8.1. Teratogenicity test — rabbit and one rodent species U.K.

6.8.2. Fertility study — at least two generations, one species, male and female U.K.

6.9. Medical data in anonymous form U.K.

6.9.1. Medical surveillance data on manufacturing plant personnel if available U.K.

6.9.2. Direct observation, e.g. clinical cases, poisoning incidents if available U.K.

6.9.3. Health records, both from industry and any other available sources U.K.

6.9.4. Epidemiological studies on the general population, if available U.K.

6.9.5. Diagnosis of poisoning including specific signs of poisoning and clinical tests, if available U.K.

6.9.6. Sensitisation/allergenicity observations, if available U.K.

6.9.7. Specific treatment in case of an accident or poisoning: first aid measures, antidotes and medical treatment, if known U.K.

6.9.8. Prognosis following poisoning U.K.

6.10. Summary of mammalian toxicology and conclusions, including no observed adverse effect level (NOAEL), no observed effect level (NOEL), overall evaluation with regard to all toxicological data and any other information concerning the active substances. Where possible any suggested worker protection measures should be included in summary form U.K.

VII. ECOTOXICOLOGICAL STUDIES U.K.

7.1. Acute toxicity to fish U.K.

7.2. Acute toxicity to Daphnia magna U.K.

7.3. Growth inhibition test on algae U.K.

7.4. Inhibition to microbiological activity U.K.

7.5. Bioconcentration U.K.

Fate and behaviour in the environment

7.6. Degradation U.K.

7.6.1. Biotic U.K.

7.6.1.1. Ready biodegradability U.K.

7.6.1.2. Inherent biodegradability, where appropriate U.K.

7.6.2. Abiotic U.K.

7.6.2.1. Hydrolysis as a function of pH and identification of breakdown products U.K.

7.6.2.2. Phototransformation in water including identity of the products of transformation (¹) U.K.

7.7. Adsorption/desorption screening test U.K.

Where the results of this test indicate the need to do so, the test described in Annex IIIA Part XII.1 paragraph 1.2 shall be required, and/or the test described in Annex IIIA Part XII.2 paragraph 2.2

7.8. Summary of ecotoxicological effects and fate and behaviour in the environment U.K.

VIII. MEASURES NECESSARY TO PROTECT MAN, ANIMALS AND THE ENVIRONMENT U.K.

8.1. Recommended methods and precautions concerning handling, use, storage, transport or fire U.K.

8.2. In case of fire, nature of reaction products, combustion gases, etc. U.K.

8.3. Emergency measures in case of an accident U.K.

8.4. Possibility of destruction or decontamination following release in or on the following: (a) air (b) water, including drinking water (c) soil U.K.

8.5. Procedures for waste management of the active substance for industry or professional users U.K.

8.5.1. Possibility of reuse or recycling U.K.

8.5.2. Possibility of neutralisation of effects U.K.

8.5.3. Conditions for controlled discharge including leachate qualities on disposal U.K.

8.5.4. Conditions for controlled incineration U.K.

8.6. Observations on undesirable or unintended side-effects, e.g. on beneficial and other non-target organisms U.K.

IX. CLASSIFICATION AND LABELLING U.K.

Proposals including justification for the proposals for the classification and labelling of the active substance according to Directive 67/548/EEC

Hazard symbol(s)

Indications of danger

Risk phrases

Safety phrases

X. SUMMARY AND EVALUATION OF SECTIONS II TO IX U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Notes U.K.

(¹) These data must be submitted for the purified active substance of stated specification. U.K.

(²) These data must be submitted for the active substance of stated specification. U.K.

(³) Eye irritation test shall not be necessary where the active substance has been shown to have potential corrosive properties. U.K.

(⁴) The long-term toxicity and carcinogenicity of an active substance may not be required where a full justification demonstrates that these tests are not necessary. U.K.

(⁵) If, in exceptional circumstances, it is claimed that such testing is unnecessary, that claim must be fully justified. U.K.

ANNEX IIB U.K. COMMON CORE DATA SET FOR BIOCIDAL PRODUCTSCHEMICAL PRODUCTS

1. Dossiers on biocidal products are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

3. Information may be derived from existing data where a justification acceptable to the competent authority is provided. In particular, the provisions of Directive 88/379/EEC should be used wherever possible to minimise animal testing. U.K.

Dossier requirements U.K.

I. Applicant U.K.

II. Identity of the biocidal product U.K.

III. Physical and chemical properties of the biocidal product U.K.

IV. Methods for identification and analysis of the biocidal product U.K.

V. Intended uses of the biocidal product and efficacy for these uses U.K.

VI. Toxicology data for the biocidal product (additional to that for the active substance) U.K.

VII. Ecotoxicology data for the biocidal product (additional to that for the active substance) U.K.

VIII. Measures necessary to protect man, animals and the environment U.K.

IX. Classification, packaging and labelling U.K.

X. Summary and evaluation of Sections II to IX U.K.

The following data will be required to support submission on the above points.

I. APPLICANT U.K.

1.1. Name and address, etc. U.K.

1.2. Formulator of the biocidal product and the active substance(s) (names, addresses, including location of plant(s)) U.K.

II. IDENTITY U.K.

2.1. Trade name or proposed trade name, and manufacturer's development code number of the preparation, if appropriate U.K.

2.2. Detailed quantitative and qualitative information on the composition of the biocidal product, e.g. active substance(s), impurities, adjutants, inert components U.K.

2.3. Physical state and nature of the biocidal product, e.g. emulsifiable concentrate, wettable powder, solution U.K.

III. PHYSICAL, CHEMICAL AND TECHNICAL PROPERTIES U.K.

3.1. Appearance (physical state, colour) U.K.

3.2. Explosive properties U.K.

3.3. Oxidising properties U.K.

3.4. Flash-point and other indications of flammability or spontaneous ignition U.K.

3.5. Acidity/alkalinity and if necessary pH value (1 % in water) U.K.

3.6. Relative density U.K.

3.7. Storage stability — stability and shelf-life. Effects of light, temperature and humidity on technical characteristics of the biocidal product; reactivity towards container material U.K.

3.8. Technical characteristics of the biocidal product, e.g. wettability, persistent foaming, flowability, pourability and dustability U.K.

3.9. Physical and chemical compatibility with other products including other biocidal products with which its use is to be authorised U.K.

IV. METHODS OF IDENTIFICATION AND ANALYSIS U.K.

4.1. Analytical method for determining the concentration of the active substance(s) in the biocidal product U.K.

4.2. In so far as not covered by Annex IIA, paragraph 4.2, analytical methods including recovery rates and the limits of determination for toxicologically and ecotoxicologically relevant components of the biocidal product and/or residues thereof, where relevant in or on the following: U.K.

(a)

Soil

(b)

Air

(c)

Water (including drinking water)

(d)

Animal and human body fluids and tissues

(e)

Treated food or feedingstuffs

V. INTENDED USES AND EFFICACY U.K.

5.1. Product type and field of use envisaged U.K.

5.2. Method of application including description of system used U.K.

5.3. Application rate and if appropriate, the final concentration of the biocidal product and active substance in the system in which the preparation is to be used, e.g. cooling water, surface water, water used for heating purposes U.K.

5.4. Number and timing of applications, and where relevant, any particular information relating to geographical variations, climatic variations, or necessary waiting periods to protect man and animals U.K.

5.5. Function, e.g. fungicide, rodenticide, insecticide, bactericide U.K.

5.6. Pest organism(s) to be controlled and products, organisms or objects to be protected U.K.

5.7. Effects on target organisms U.K.

5.8. Mode of action (including time delay) in so far as not covered by Annex IIA, paragraph 5.4 U.K.

5.9. User: industrial, professsional, general public (non-professional) U.K.

Efficacy data

5.10. The proposed label claims for the product and efficacy data to support these claims, including any available standard protocols used, laboratory tests, or field trials, where appropriate U.K.

5.11. Any other known limitations on efficacy including resistance U.K.

VI. TOXICOLOGICAL STUDIES U.K.

6.1. Acute toxicity U.K.

For studies 6.1.1 to 6.1.3, biocidal products other than gases shall be administered via at least two routes, one of which should be the oral route. The choice of the second route will depend on the nature of the product and the likely route of human exposure. Gases and volatile liquids should be administered by the inhalation route

6.1.1. Oral U.K.

6.1.2. Dermal U.K.

6.1.3. Inhalation U.K.

6.1.4. For biocidal products that are intended to be authorised for use with other biocidal products, the mixture of products, where possible, shall be tested for acute dermal toxicity and skin and eye irritation, as appropriate U.K.

6.2. Skin and eye irritation (¹) U.K.

6.3. Skin sensitisation U.K.

6.4. Information on dermal absorption U.K.

6.5. Available toxicological data relating to toxicologically relevant non-active substances (i.e. substances of concern) U.K.

6.6. Information related to the exposure of the biocidal product to man and the operator U.K.

Where necessary, the test(s) described in Annex IIA, shall be required for the toxicologically relevant non-active substances of the preparation

VII. ECOTOXICOLOGICAL STUDIES U.K.

7.1. Foreseeable routes of entry into the environment on the basis of the use envisaged U.K.

7.2. Information on the ecotoxicology of the active substance in the product, where this cannot be extrapolated from the information on the active substance itself U.K.

7.3. Available ecotoxicological information relating to exotoxicological relevant non-active substances (i.e. substances of concern), such as information from safety data sheets U.K.

VIII. MEASURES TO BE ADOPTED TO PROTECT MAN, ANIMALS AND THE ENVIRONMENT U.K.

8.1. Recommended methods and precautions concerning handling, use, storage, transport or fire U.K.

8.2. Specific treatment in case of an accident, e.g. first-aid measures, antidotes, medical treatment if available; emergency measures to protect the environment; in so far as not covered by Annex IIA, paragraph 8.3 U.K.

8.3. Procedures, if any, for cleaning application equipment U.K.

8.4. Identity of relevant combustion products in cases of fire U.K.

8.5. Procedures for waste management of the biocidal product and its packaging for industry, professional users and the general public (non-professional users), e.g. possibility of reuse or recycling, neutralisation, conditions for controlled discharge, and incineration U.K.

8.6. Possibility of destruction or decontamination following release in or on the following: U.K.

(a)

Air

(b)

Water, including drinking water

(c)

Soil

8.7. Observations on undesirable or unintended side-effects, e.g. on beneficial and other non-target organisms U.K.

8.8. Specify any repellents or poison control measures included in the preparation that are present to prevent action against non-target organisms U.K.

IX. CLASSIFICATION, PACKAGING AND LABELLING U.K.

• Proposals for packaging and labelling

• Proposals for safety-data sheets, where appropriate

• Justification for the classification and labelling according to the principles of Article 20 of this Directive

  • Hazard symbol(s)

  • Indications of danger

  • Risk phrases

  • Safety phrases

  • Packaging (type, materials, size, etc.), compatibility of the preparation with proposed packaging materials to be included

X. SUMMARY AND EVALUATION OF SECTIONS II TO IX U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Notes U.K.

(¹) Eye-irritation test shall not be necessary where the biocidal product has been shown to have potential corrosive properties. U.K.

ANNEX IIIA U.K. ADDITIONAL DATA SET FOR ACTIVE SUBSTANCESCHEMICAL SUBSTANCES

1. Dossiers on active substances are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

III. PHYSICAL AND CHEMICAL PROPERTIES U.K.

1. Solubility in organic solvents, including effect of temperature on solubility (¹) U.K.

2. Stability in organic solvents used in biocidal products and identity of relevant breakdown products (²) U.K.

IV. ANALYTICAL METHODS FOR DETECTION AND IDENTIFICATION U.K.

1. Analytical methods including recovery rates and the limits of determination for the active substance, and for residues thereof, in/on food or feedstuffs and other products where relevant U.K.

VI. TOXICOLOGICAL AND METABOLIC STUDIES U.K.

1. Neurotoxicity study U.K.

If the active substance is an organophosphorus compound or if there are any other indications that the active substance may have neurotoxic properties then neurotoxicity studies will be required. The test species is the adult hen unless another test species is justified to be more appropriate. If appropriate, delayed neurotoxicity tests will be required. If anticholine esterase activity is detected a test for response to reactivating agents should be considered

2. Toxic effects on livestock and pets U.K.

3. Studies related to the exposure of the active substance to humans U.K.

4. Food and feedingstuffs U.K.

If the active substance is to be used in preparations for use where food for human consumption is prepared, consumed or stored, or where feedingstuff for livestock is prepared, consumed or stored the tests referred to in Section XI, part 1 shall be required

5. If any other tests related to the exposure of the active substance to humans, in its proposed biocidal products, are considered necessary, then the test(s) referred to in Section XI, part 2 shall be required U.K.

6. If the active substance is to be used in products for action against plants then tests to assess toxic effects of metabolites from treated plants, if any, where different from those identified in animals shall be required U.K.

7. Mechanistic study — any studies necessary to clarify effects reported in toxicity studies U.K.

VII. ECOTOXICOLOGICAL STUDIES U.K.

1. Acute toxicity test on one other, non-aquatic, non-target organism U.K.

2. If the results of the ecotoxicological studies and the intended use(s) of the active substance indicate a danger for the environment then the tests described in Sections XII and XIII shall be required U.K.

3. If the result of the test in paragraph 7.6.1.2 of Annex IIA is negative and if the likely route of disposal of the active substance is by sewage treatment then the test described in Section XIII, part 4.1 shall be required U.K.

4. Any other biodegradability tests that are relevant from the results in paragraphs 7.6.1.1 and 7.6.1.2 of Annex IIA U.K.

5. Phototransformation in air (estimation method), including identification of breakdown products (¹) U.K.

6. If the results from paragraphs 7.6.1.2 in Annex IIA or from paragraph 4, above, indicate the need to do so, or the active substance has an overall low or absent abiotic degradation, then the tests described in Section XII, part 1.1, part 2.1 and, where appropriate, part 3 shall be required U.K.

VIII. MEASURES NECESSARY TO PROTECT HUMANS, ANIMALS AND THE ENVIRONMENT U.K.

1. Identification of any substances falling within the scope of List I or List II of the Annex to Directive 80/68/EEC on the protection of groundwater against pollution caused by certain dangerous substances(3) U.K.

Notes U.K.

(¹) These data must be submitted for the purified active substance of stated specification. U.K.

(²) These data must be submitted for the active substance of stated specification. U.K.

XI. FURTHER HUMAN HEALTH-RELATED STUDIES U.K.

1. Food and feedingstuffs studies U.K.

1.1. Identification of degradation and reaction products and of metabolites of the active substance in treated or contaminated foods or feedstuffs U.K.

1.2. Behaviour of the residue of the active substance, its degradation products and, where relevant, its metabolites on the treated or contaminated food or feedstuffs including the kinetics of disappearance U.K.

1.3. Overall material balance for the active substance. Sufficient residue data from supervised trials to demonstrate that residues likely to arise from the proposed use would not be of concern for human or animal health U.K.

1.4. Estimation of potential or actual exposure of the active substance to humans through diet and other means U.K.

1.5. If residues of the active substance remain on feedingstuffs for a significant period of time then feeding and metabolism studies in livestock shall be required to permit evaluation of residues in food of animal origin U.K.

1.6. Effects of industrial processing and/or domestic preparation on the nature and magnitude of residues of the active substance U.K.

1.7. Proposed acceptable residues and the justification of their acceptability U.K.

1.8. Any other available information that is relevant U.K.

1.9. Summary and evaluation of data submitted under 1.1 to 1.8 U.K.

2. Other test(s) related to the exposure to humans U.K.

Suitable test(s) and a reasoned case will be required

XII. FURTHER STUDIES ON FATE AND BEHAVIOUR IN THE ENVIRONMENT U.K.

1. Fate and behaviour in soil U.K.

1.1. Rate and route of degradation including identification of the processes involved and identification of any metabolites and degradation products in at least three soil types under appropriate conditions U.K.

1.2. Absorption and desorption in at least three soil types and, where relevant, absorption and desorption of metabolites and degradation products U.K.

1.3. Mobility in at least three soil types and where relevant mobility of metabolites and degradation products U.K.

1.4. Extent and nature of bound residues U.K.

2. Fate and behaviour in water U.K.

2.1. Rate and route of degradation in aquatic systems (as far as is not covered by Annex IIA, paragraph 7.6) including identification of metabolites and degradation products U.K.

2.2. Absorption and desorption in water (soil sediment systems) and, where relevant, absorption and desorption of metabolites and degradation products U.K.

3. Fate and behaviour in air U.K.

If the active substance is to be used in preparations for fumigants, if it is to be applied by a spray method, if it is volatile, or if any other information indicates that this is relevant, then the rate and route of degradation in air shall be determined as far as is not covered by Section VII, part 5

4. Summary and evaluation of parts 1, 2 and 3 U.K.

XIII. FURTHER ECOTOXICOLOGICAL STUDIES U.K.

1. Effects on birds U.K.

1.1. Acute oral toxicity — this need not be done if an avian species was selected for study in Section VII, part 1 U.K.

1.2. Short-term toxicity — eight-day dietary study in at least one species (other than chickens) U.K.

1.3. Effects on reproduction U.K.

2. Effects on aquatic organisms U.K.

2.1. Prolonged toxicity to an appropriate species of fish U.K.

2.2. Effects on reproduction and growth rate on an appropriate species of fish U.K.

2.3. Bioaccumulation in an appropriate species of fish U.K.

2.4. Daphnia magna reproduction and growth rate U.K.

3. Effects on other non-target organisms U.K.

3.1. Acute toxicity to honeybees and other beneficial arthropods, e.g. predators. A different test organism shall be chosen from that used in Section VII, part 1 U.K.

3.2. Toxicity to earthworms and to other soil non-target macro-organisms U.K.

3.3. Effects on soil non-target micro-organisms U.K.

3.4. Effects on any other specific, non-target organisms (flora and fauna) believed to be at risk U.K.

4. Other effects U.K.

4.1. Activated sludge respiration inhibition test U.K.

5. Summary and evaluation of parts 1, 2, 3 and 4 U.K.

ANNEX IIIB U.K. ADDITIONAL DATA SET FOR BIOCIDAL PRODUCTSCHEMICAL PRODUCTS

1. Dossiers on biocidal products are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

3. Information may be derived from existing data where a justification acceptable to the competent authority is provided. In particular, the provisions of Directive 88/379/EEC should be used wherever possible to minimise animal testing. U.K.

XI. FURTHER HUMAN HEALTH-RELATED STUDIES U.K.

1. Food and feedingstuffs studies U.K.

1.1. If residues of the biocidal product remain on feedingstuffs for a significant period of time, then feeding and metabolism studies in livestock shall be required to permit evaluation of residues in food of animal origin U.K.

1.2. Effects of industrial processing and/or domestic preparation on the nature and magnitude of residues of the biocidal product U.K.

2. Other test(s) related to the exposure to humans U.K.

Suitable test(s) and a reasoned case will be required for the biocidal product

XII. FURTHER STUDIES ON FATE AND BEHAVIOUR IN THE ENVIRONMENT U.K.

1. Where relevant all the information required in Annex IIIA, Section XII U.K.

2. Testing for distribution and dissipation in the following: U.K.

(a)

Soil

(b)

Water

(c)

Air

Test requirements 1 and 2 above are applicable only to ecotoxicologically relevant components of the biocidal product

XIII. FURTHER ECOTOXICOLOGICAL STUDIES U.K.

1. Effects on birds U.K.

1.1. Acute oral toxicity, if not already done in accordance with Annex IIB, Section VII U.K.

2. Effects on aquatic organisms U.K.

2.1. In case of application on, in, or near to surface waters U.K.

2.1.1. Particular studies with fish and other aquatic organisms U.K.

2.1.2. Residue data in fish concerning the active substance and including toxicologically relevant metabolites U.K.

2.1.3. The studies referred to in Annex IIIA, Section XIII, parts 2.1, 2.2, 2.3 and 2.4 may be required for relevant components of the biocidal product U.K.

2.2. If the biocidal product is to be sprayed near to surface waters then an overspray study may be required to assess risks to aquatic organisms under field conditions U.K.

3. Effects on other non-target organisms U.K.

3.1. Toxicity to terrestrial vertebrates other than birds U.K.

3.2. Acute toxicity to honeybees U.K.

3.3. Effects on beneficial arthropods other than bees U.K.

3.4. Effects on earthworms and other soil non-target macro-organisms, believed to be at risk U.K.

3.5. Effects on soil non-target micro-organisms U.K.

3.6. Effects on any other specific, non-target organisms (flora and fauna) believed to be at risk U.K.

3.7. If the biocidal product is in the form of bait or granules U.K.

3.7.1. Supervised trials to assess risks to non-target organisms under field conditions U.K.

3.7.2. Studies on acceptance by ingestion of the biocidal product by any non-target organisms thought to be at risk U.K.

4. Summary and evaluation of parts 1, 2, and 3 U.K.

[F55 ANNEX IVA U.K. DATA SET FOR ACTIVE SUBSTANCES MICRO-ORGANISMS INCLUDING VIRUSES AND FUNGI

Textual Amendments

F55 Substituted by Commission Directive 2006/50/EC of 29 May 2006 amending Annexes IVA and IVB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (Text with EEA relevance).

1. For the purposes of this Annex, the term micro-organisms shall be understood as including also viruses and fungi. Dossiers on active micro-organisms shall address at least all the points listed under ‘ Dossier requirements ’ below. For all micro-organisms subject to an application for inclusion into Annex I or IA, all available relevant knowledge and information in literature must be provided. The information related to the identification and characterisation of a micro-organism including mode of action is particularly important and must be entered in sections I to IV and provides the basis for an assessment of potential impacts on human health and of environmental effects. U.K.

2. Where information is not necessary owing to the nature of the micro-organism Article 8(5) shall apply. U.K.

3. A dossier within the meaning of Article 11(1) shall be prepared on strain level of the micro-organism unless information is submitted that shows that the species is known to be sufficiently homogeneous regarding all characteristics, or the applicant provides other arguments in accordance with Article 8(5). U.K.

4. Where the micro-organism has been genetically modified within the meaning of Article 2(2) of Directive 2001/18/EC, a copy of the evaluation of the data concerning the assessment of the risks to the environment as established in Article 4(2) of that Directive, shall also be submitted. U.K.

5. If the biocidal product action is known to be partly or entirely due to the effect of a toxin/metabolite, or if significant residues of toxins/metabolites are to be expected not related to the effect of the active micro-organism, a dossier for the toxin/metabolite shall be submitted in accordance with the requirements of Annexes IIA and, where specified, the relevant parts of Annex IIIA. U.K.

Dossier requirements U.K.

SECTIONS:

I.

Identity of the micro-organism

II.

Biological properties of the micro-organism

III.

Further information on the micro-organism

IV.

Analytical methods

V.

Effects on human health

VI.

Residues in or on treated materials, food and feed

VII.

Fate and behaviour in the environment

VIII.

Effects on non-target organisms

IX.

Classification and labelling

X.

Summary and evaluation of sections I to IX including conclusions of the risk assessment and recommendations

The following data will be required to support submissions on the above points.

I. IDENTITY OF THE MICRO-ORGANISM U.K.

1.1. Applicant U.K.

1.2. Manufacturer U.K.

1.3. Name and species description, strain characterisation U.K.

1.3.1. Common name of the micro-organism (including alternative and superseded names) U.K.

1.3.2. Taxonomic name and strain indicating whether it is a stock variant, a mutant strain or a genetically modified organism (GMO); for viruses, taxonomic designation of the agent, serotype, strain or mutant U.K.

1.3.3. Collection and culture reference number where the culture is deposited U.K.

1.3.4. Methods, procedures and criteria used to establish the presence and identity of the micro-organism (e.g. morphology, biochemistry, serology, etc.) U.K.

1.4. Specification of the material used for manufacturing of formulated products U.K.

1.4.1. Content of the micro-organism U.K.

1.4.2. Identity and content of impurities, additives, contaminating micro-organisms U.K.

1.4.3. Analytical profile of batches U.K.

II. BIOLOGICAL PROPERTIES OF THE MICRO-ORGANISM U.K.

2.1. History of the micro-organism and its uses. Natural occurrence and geographical distribution U.K.

2.1.1. Historical background U.K.

2.1.2. Origin and natural occurrence U.K.

2.2. Information on target organism(s) U.K.

2.2.1. Description of the target organism(s) U.K.

2.2.2. Mode of action U.K.

2.3. Host specificity range and effects on species other than the target organism U.K.

2.4. Development stages/life cycle of the micro-organism U.K.

2.5. Infectiveness, dispersal and colonisation ability U.K.

2.6. Relationships to known plant or animal or human pathogens U.K.

2.7. Genetic stability and factors affecting it U.K.

2.8. Information on the production of metabolites (especially toxins) U.K.

2.9. Antibiotics and other anti-microbial agents U.K.

2.10. Robustness to environmental factors U.K.

2.11. Effects on materials, substances and products U.K.

III. FURTHER INFORMATION ON THE MICRO-ORGANISM U.K.

3.1. Function U.K.

3.2. Field of use envisaged U.K.

3.3. Product type(s) and category of users for which the micro-organism should be listed in Annex I, IA or IB U.K.

3.4. Method of production and quality control U.K.

3.5. Information on the occurrence or possible occurrence of the development of resistance of the target organism(s) U.K.

3.6. Methods to prevent loss of virulence of seed stock of the micro-organism U.K.

3.7. Recommended methods and precautions concerning handling, storage, transport or fire U.K.

3.8. Procedures for destruction or decontamination U.K.

3.9. Measures in case of an accident U.K.

3.10. Procedures for waste management U.K.

3.11. Monitoring plan to be used for the active micro-organism including handling, storage, transport and use U.K.

IV. ANALYTICAL METHODS U.K.

4.1. Methods for the analysis of the micro-organism as manufactured U.K.

4.2. Methods to determine and quantify residues (viable or non-viable) U.K.

V. EFFECTS ON HUMAN HEALTH U.K.

TIER I U.K.

5.1. Basic information U.K.

5.1.1. Medical data U.K.

5.1.2. Medical surveillance on manufacturing plant personnel U.K.

5.1.3. Sensitisation/allergenicity observations U.K.

5.1.4. Direct observation, e.g. clinical cases U.K.

5.2. Basic studies U.K.

5.2.1. Sensitisation U.K.

5.2.2. Acute toxicity, pathogenicity, and infectiveness U.K.

5.2.2.1. Acute oral toxicity, pathogenicity and infectiveness U.K.

5.2.2.2. Acute inhalation toxicity, pathogenicity and infectiveness U.K.

5.2.2.3. Intraperitoneal/subcutaneous single dose U.K.

5.2.3. In vitro genotoxicity testing U.K.

5.2.4. Cell culture study U.K.

5.2.5. Information on short-term toxicity and pathogenicity U.K.

5.2.5.1. Health effects after repeated inhalatory exposure U.K.

5.2.6. Proposed treatment: first aid measures, medical treatment U.K.

5.2.7. Any pathogenicity and infectiveness to humans and other mammals under conditions of immunosuppression U.K.

END OF TIER I U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

TIER II U.K.

5.3. Specific toxicity, pathogenicity and infectiveness studies U.K.

5.4. Genotoxicity — In vivo studies in somatic cells U.K.

5.5. Genotoxicity — In vivo studies in germ cells U.K.

END OF TIER II U.K.

5.6. Summary of mammalian toxicity, pathogenicity and infectiveness and overall evaluation U.K.

VI. RESIDUES IN OR ON TREATED MATERIALS, FOOD AND FEED U.K.

6.1. Persistence and likelihood of multiplication in or on treated materials, feedingstuffs or foodstuffs U.K.

6.2. Further information required U.K.

6.2.1. Non-viable residues U.K.

6.2.2. Viable residues U.K.

6.3. Summary and evaluation of residues in or on treated materials, food and feed U.K.

VII. FATE AND BEHAVIOUR IN THE ENVIRONMENT U.K.

7.1. Persistence and multiplication U.K.

7.1.1. Soil U.K.

7.1.2. Water U.K.

7.1.3. Air U.K.

7.2. Mobility U.K.

7.3. Summary and evaluation of fate and behaviour in the environment U.K.

VIII. EFFECTS ON NON-TARGET ORGANISMS U.K.

8.1. Effects on birds U.K.

8.2. Effects on aquatic organisms U.K.

8.2.1. Effects on fish U.K.

8.2.2. Effects on freshwater invertebrates U.K.

8.2.3. Effects on algae growth U.K.

8.2.4. Effects on plants other than algae U.K.

8.3. Effects on bees U.K.

8.4. Effects on arthropods other than bees U.K.

8.5. Effects on earthworms U.K.

8.6. Effects on soil micro-organisms U.K.

8.7. Further studies U.K.

8.7.1. Terrestrial plants U.K.

8.7.2. Mammals U.K.

8.7.3. Other relevant species and processes U.K.

8.8. Summary and evaluation of effects on non-target organisms U.K.

IX. CLASSIFICATION AND LABELLING U.K.

The dossier shall be accompanied by a reasoned proposals for allocating an active substance which is a micro-organism to one of the risk groups specified in Article 2 of Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (4) together with indications on the need for products to carry the biohazard sign specified in Annex II to that Directive.

X. SUMMARY AND EVALUATION OF SECTIONS I TO IX INCLUDING CONCLUSIONS OF THE RISK ASSESSMENT AND RECOMMENDATIONS U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ANNEX IVB U.K. DATA SET FOR BIOCIDAL PRODUCTS MICRO-ORGANISMS INCLUDING VIRUSES AND FUNGI

1. For the purposes of this Annex, the term micro-organisms shall be understood as including also viruses and fungi. This Annex provides data requirements for the authorisation of a biocidal product based on preparations of micro-organisms. For all biocidal products based on preparations containing micro-organisms that are subject to application, all available relevant knowledge and information in literature should be provided. The information related to the identification and characterisation of all components in a biocidal product is particularly important and must be entered in sections I to IV and provides the basis for an assessment of possible impacts on human health and the environment. U.K.

2. Where, information is not necessary owing to the nature of the biocidal product Article 8(5) shall apply. U.K.

3. Information may be derived from existing data where a justification acceptable to the competent authority is provided. In particular, the provisions of Directive 67/548/EEC and Directive 1999/45/EC of the European Parliament and of the Council of 31 May 1999 concerning the approximation of the laws, regulations and administrative provisions of the Member States relating to the classification, packaging and labelling of dangerous preparations (5) shall be used wherever possible to minimise animal testing. U.K.

4. Where testing is done, a detailed description (specification) of the material used and its impurities, according to the provisions of Section II, must be provided. Where necessary, data as established in Annexes IIB, IIIB shall be required for all the toxicologically/eco-toxicologically relevant chemical components of the biocidal product, in particular if the components are substances of concern as defined in Article 2(1)(e). U.K.

5. In cases where a new preparation is to be dealt with, extrapolation from Annex IVA, could be acceptable, provided that all the possible effects of the components, especially on pathogenicity and infectiveness, are evaluated. U.K.

Dossier requirements U.K.

SECTIONS:

I.

Identity of the biocidal product

II.

Physical, chemical and technical properties of the biocidal product

III.

Data on application

IV.

Further information on the biocidal product

V.

Analytical methods

VI.

Efficacy data

VII.

Effects on human health

VIII.

Residues in or on treated materials, food and feed

IX.

Fate and behaviour in the environment

X.

Effects on non-target organisms

XI.

Classification, packaging and labelling of the biocidal product

XII.

Summary and evaluation of sections I to XI including conclusions of the risk assessment and recommendations

The following data will be required to support submissions on the above points.

I. IDENTITY OF THE BIOCIDAL PRODUCTS U.K.

1.1. Applicant U.K.

1.2. Manufacturer of the biocidal product and the micro-organism(s) U.K.

1.3. Trade name or proposed trade name, and manufacturer's development code number of the biocidal product U.K.

1.4. Detailed quantitative and qualitative information on the composition of the biocidal product U.K.

1.5. Physical state and nature of the biocidal product U.K.

1.6. Function U.K.

II. PHYSICAL, CHEMICAL AND TECHNICAL PROPERTIES OF THE BIOCIDAL PRODUCT U.K.

2.1. Appearance (colour and odour) U.K.

2.2. Storage stability and shelf-life U.K.

2.2.1. Effects of light, temperature and humidity on technical characteristics of the biocidal product U.K.

2.2.2. Other factors affecting stability U.K.

2.3. Explosivity and oxidising properties U.K.

2.4. Flash point and other indications of flammability or spontaneous ignition U.K.

2.5. Acidity, alkalinity and pH value U.K.

2.6. Viscosity and surface tension U.K.

2.7. Technical characteristics of the biocidal product U.K.

2.7.1. Wettability U.K.

2.7.2. Persistent foaming U.K.

2.7.3. Suspensibility and suspension stability U.K.

2.7.4. Dry sieve test and wet sieve test U.K.

2.7.5. Particle size distribution (dustable and wettable powders, granules), content of dust/fines (granules), attrition and friability (granules) U.K.

2.7.6. Emulsifiability, re-emulsifiability, emulsion stability U.K.

2.7.7. Flowability, pourability (rinsability) and dustability U.K.

2.8. Physical, chemical and biological compatibility with other products including biocidal products with which its use is to be authorised or registered U.K.

2.8.1. Physical compatibility U.K.

2.8.2. Chemical compatibility U.K.

2.8.3. Biological compatibility U.K.

2.9. Summary and evaluation of physical, chemical and technical properties of the biocidal product U.K.

III. DATA ON APPLICATION U.K.

3.1. Field of use envisaged U.K.

3.2. Mode of action U.K.

3.3. Details of intended use U.K.

3.4. Application rate U.K.

3.5. Content of micro-organism in material used (e.g. in the application device or bait) U.K.

3.6. Method of application U.K.

3.7. Number and timing of applications and duration of protection U.K.

3.8. Necessary waiting periods or other precautions to avoid adverse effects to human and animal health and the environment U.K.

3.9. Proposed instructions for use U.K.

3.10. Category of users U.K.

3.11. Information on the possible occurrence of the development of resistance U.K.

3.12. Effects on the materials or products treated with the biocidal product U.K.

IV. FURTHER INFORMATION ON THE BIOCIDAL PRODUCT U.K.

4.1. Packaging and compatibility of the biocidal product with proposed packaging materials U.K.

4.2. Procedures for cleaning application equipment U.K.

4.3. Re-entry periods, necessary waiting periods or other precautions to protect man, livestock and the environment U.K.

4.4. Recommended methods and precautions concerning: handling, storage, transport or fire U.K.

4.5. Measures in the case of an accident U.K.

4.6. Procedures for destruction or decontamination of the biocidal product and its packaging U.K.

4.6.1. Controlled incineration U.K.

4.6.2. Others U.K.

4.7. Monitoring plan to be used for the active micro-organism and other micro-organism(s) contained in the biocidal product including handling, storage, transport and use U.K.

V. ANALYTICAL METHODS U.K.

5.1. Methods for the analysis of the biocidal product U.K.

5.2. Methods to determine and quantify residues U.K.

VI. EFFICACY DATA U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

VII. EFFECTS ON HUMAN HEALTH U.K.

7.1. Basic acute toxicity studies U.K.

7.1.1. Acute oral toxicity U.K.

7.1.2. Acute inhalation toxicity U.K.

7.1.3. Acute percutaneous toxicity U.K.

7.2. Additional acute toxicity studies U.K.

7.2.1. Skin irritation U.K.

7.2.2. Eye irritation U.K.

7.2.3. Skin sensitisation U.K.

7.3. Data on exposure U.K.

7.4. Available toxicological data relating to non-active substances U.K.

7.5. Supplementary studies for combinations of biocidal products U.K.

7.6. Summary and evaluation of effects on human health U.K.

VIII. RESIDUES IN OR ON TREATED MATERIALS, FOOD AND FEED U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

IX. FATE AND BEHAVIOUR IN THE ENVIRONMENT U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

X. EFFECTS ON NON-TARGET ORGANISMS U.K.

10.1. Effects on birds U.K.

10.2. Effects on aquatic organisms U.K.

10.3. Effects on bees U.K.

10.4. Effects on arthropods other than bees U.K.

10.5. Effects on earthworms U.K.

10.6. Effects on soil micro-organisms U.K.

10.7. Additional studies on additional species or higher tier studies such as studies on selected non-target organisms U.K.

10.7.1. Terrestrial plants U.K.

10.7.2. Mammals U.K.

10.7.3. Other relevant species and processes U.K.

10.8. Summary and evaluation of effects on non-target organisms U.K.

XI. CLASSIFICATION, PACKAGING AND LABELLING OF THE BIOCIDAL PRODUCT U.K.

As established in Article 20, proposals including justification for the classification and labelling of the biocidal product in accordance with the provisions set in Directive 67/548/EEC and Directive 1999/45/EC must be submitted. The classification comprises of the description of the category/categories of danger and qualifying risk phrases for all dangerous properties. On the basis of the classification, a proposal for labelling including the hazard symbol(s) and indications of danger, risk phrases and safety phrases should be given. The classification and labelling shall be in regard to the chemical substances contained in the biocidal product. If necessary, specimens of proposed packaging shall be submitted to the competent authority of a Member State.

The dossier shall be accompanied by a reasoned proposal for allocation to one of the risk groups specified in Article 2 of Directive 2000/54/EC together with indications on the need for products to carry the biohazard sign specified in Annex II to that Directive.

XII. SUMMARY AND EVALUATION OF SECTIONS I TO XI INCLUDING CONCLUSIONS OF THE RISK ASSESSMENT AND RECOMMENDATIONS] U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ANNEX V U.K. BIOCIDAL PRODUCT-TYPES AND THEIR DESCRIPTIONS AS REFERRED TO IN ARTICLE 2(1)(a) OF THIS DIRECTIVE

These product-types exclude products where they are covered by the Directives mentioned in Article 1(2) of this Directive for the purposes of these Directives and their subsequent modifications.

MAIN GROUP 1: Disinfectants and general biocidal products U.K.

These product types exclude cleaning products that are not intended to have a biocidal effect, including washing liquids, powders and similar products.

Product-type 1: Human hygiene biocidal products U.K.

Products in this group are biocidal products used for human hygiene purposes.

Product-type 2: Private area and public health area disinfectants and other biocidal products U.K.

Products used for the disinfection of air, surfaces, materials, equipment and furniture which are not used for direct food or feed contact in private, public and industrial areas, including hospitals, as well as products used as algaecides.

Usage areas include, inter alia, swimming pools, aquariums, bathing and other waters; air-conditioning systems; walls and floors in health and other institutions; chemical toilets, waste water, hospital waste, soil or other substrates (in playgrounds).

Product-type 3: Veterinary hygiene biocidal products U.K.

Products in this group are biocidal products used for veterinary hygiene purposes including products used in areas in which animals are housed, kept or transported.

Product-type 4: Food and feed area disinfectants U.K.

Products used for the disinfection of equipment, containers, consumption utensils, surfaces or pipework associated with the production, transport, storage or consumption of food, feed or drink (including drinking water) for humans and animals.

Product-type 5: Drinking water disinfectants U.K.

Products used for the disinfection of drinking water (for both humans and animals).

MAIN GROUP 2: Preservatives U.K.

Product-type 6: In-can preservatives U.K.

Products used for the preservation of manufactured products, other than foodstuffs or feedingstuffs, in containers by the control of microbial deterioration to ensure their shelf life.

Product-type 7: Film preservatives U.K.

Products used for the preservation of films or coatings by the control of microbial deterioration in order to protect the initial properties of the surface of materials or objects such as paints, plastics, sealants, wall adhesives, binders, papers, art works.

Product-type 8: Wood preservatives U.K.

Products used for the preservation of wood, from and including the saw-mill stage, or wood products by the control of wood-destroying or wood-disfiguring organisms.

This product type includes both preventive and curative products.

Product-type 9: Fibre, leather, rubber and polymerised materials preservatives U.K.

Products used for the preservation of fibrous or polymerised materials, such as leather, rubber or paper or textile products and rubber by the control of microbiological deterioration.

Product-type 10: Masonry preservatives U.K.

Products used for preservation and remedial treatment of masonry or other construction materials other than wood by the control of microbiological and algal attack.

Product-type 11: Preservatives for liquid-cooling and processing systems U.K.

Products used for the preservation of water or other liquids used in cooling and processing systems by the control of harmful organisms such as microbes, algae and mussels.

Products used for the preservation of drinking water are not included in this product type.

Product-type 12: Slimicides U.K.

Products used for the prevention or control of slime growth on materials, equipment and structures, used in industrial processes, e.g. on wood and paper pulp, porous sand strata in oil extraction.

Product-type 13: Metalworking-fluid preservatives U.K.

Products used for the preservation of metalworking fluids by the control of microbial deterioration.

MAIN GROUP 3: Pest control U.K.

Product-type 14: Rodenticides U.K.

Products used for the control of mice, rats or other rodents.

Product-type 15: Avicides U.K.

Products used for the control of birds.

Product-type 16: Molluscicides U.K.

Products used for the control of molluscs.

Product-type 17: Piscicides U.K.

Products used for the control of fish; these products exclude products for the treatment of fish diseases.

Product-type 18: Insecticides, acaricides and products to control other arthropods U.K.

Products used for the control of arthropods (e.g. insects, arachnids and crustaceans).

Product-type 19: Repellents and attractants U.K.

Products used to control harmful organisms (invertebrates such as fleas, vertebrates such as birds), by repelling or attracting, including those that are used for human or veterinary hygiene either directly or indirectly.

MAIN GROUP 4: Other biocidal products U.K.

Product-type 20: Preservatives for food or feedstocks U.K.

Products used for the preservation of food or feedstocks by the control of harmful organisms.

Product-type 21: Antifouling products U.K.

Products used to control the growth and settlement of fouling organisms (microbes and higher forms of plant or animal species) on vessels, aquaculture equipment or other structures used in water.

Product-type 22: Embalming and taxidermist fluids U.K.

Products used for the disinfection and preservation of human or animal corpses, or parts thereof.

Product-type 23: Control of other vertebrates U.K.

Products used for the control of vermin.

ANNEX VI U.K. COMMON PRINCIPLES FOR THE EVALUATION OF DOSSIERS FOR BIOCIDAL PRODUCTS

CONTENTS U.K.

Definitions U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Introduction U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Evaluation U.K.

• General principles

• Effects on humans

• Effects on animals

• Effects on the environment

• Unacceptable effects

• Efficacy

• Summary

Decision-making U.K.

• General principles

• Effects on humans

• Effects on animals

• Effects on the environment

• Unacceptable effects

• Efficacy

• Summary

Overall integration of conclusions U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

DEFINITIONS U.K.

(a) Hazard identification U.K.

This is the identification of the adverse effects which a biocidal product has an inherent capacity to cause.

(b) Dose (concentration) — response (effect) assessment U.K.

This is the estimate of the relationship between the dose, or level of exposure, of an active substance or substance of concern in a biocidal product and the incidence and severity of an effect.

(c) Exposure assessment U.K.

This is the determination of the emissions, pathways and rates of movement of an active substance or a substance of concern in a biocidal product and its transformation or degradation in order to estimate the concentration/doses to which human populations, animals or environmental compartments are or may be exposed.

(d) Risk characterisation U.K.

This is the estimation of the incidence and severity of the adverse effects likely to occur in a human population, animals or environmental compartments due to actual or predicted exposure to any active substance or substance of concern in a biocidal product. This may include ‘risk estimation’ i.e. the quantification of that likelihood.

(e) Environment U.K.

Water, including sediment, air, land, wild species of fauna and flora, and any interrelationship between them, as well as any relationship with living organisms.

INTRODUCTION U.K.

1. This Annex lays down principles to ensure that evaluations made and decisions taken by a Member State concerning the authorisation of a biocidal product providing it is a chemical preparation results in a harmonised high level of protection for humans, animals and the environment in accordance with Article 5(1)(b) of this Directive. U.K.

2. In order to ensure a high and harmonised level of protection of human and animal health and of the environment, any risks arising from the use of a biocidal product shall be identified. To achieve this a risk assessment shall be carried out to determine the acceptability or otherwise of any risks identified during the proposed normal use of the biocidal product. This is done by carrying out an assessment of the risks associated with the relevant individual components of the biocidal product. U.K.

3. A risk assessment on the active substance or substances present in the biocidal product is always required. This will already have been carried out for the purpose of Annexes I, IA or IB. This risk assessment shall entail hazard identification, and, as appropriate, dose (concentration) — response (effect) assessment, exposure assessment and risk characterisation. Where a quantitative risk assessment cannot be made a qualitative assessment shall be produced. U.K.

4. Additional risk assessments shall be carried out, in the same manner as described above, on any other substance of concern present in the biocidal product where relevant for the use of the biocidal product. U.K.

5. In order to carry out a risk assessment data are required. These data are detailed in Annexes II, III and IV and, recognising that there are a wide variety of product types, are flexible according to the product type and associated risks. The data required shall be the minimum necessary to carry out an appropriate risk assessment. Member States should take due consideration of the requirements of Articles 12 and 13 of this Directive in order to avoid duplication of data submissions. The minimum set of data required for an active substance in any biocidal product type, however, shall be that detailed in Annex VIIA to Directive 67/548/EEC; these data will already have been submitted and assessed as part of the risk assessment required for entry of the active substance into Annex I, IA or IB to this Directive. Data may also be required on a substance of concern present in a biocidal product. U.K.

6. The results of the risk assessments carried out on an active substance and on a substance of concern present in the biocidal product shall be integrated to produce an overall assessment for the biocidal product itself. U.K.

7. When making evaluations and taking decisions concerning the authorisation of a biocidal product the Member State shall: U.K.

(a)

take into consideration other relevant technical or scientific information which is reasonably available to them with regard to the properties of the biocidal product, its components, metabolites, or residues;

(b)

evaluate, where relevant, justifications submitted by the applicant for not supplying certain data.

8. The Member State shall comply with the requirements of mutual recognition as stated in Articles 4(1), (2) and (6) of this Directive. U.K.

9. It is known that many biocidal products present only minor differences in composition and this should be taken into account when evaluating dossiers. The concept of ‘frame-formulations’ is relevant here. U.K.

10. It is known that certain biocidal products are considered as posing only a low risk, these biocidal products, while complying with the requirements of this Annex, are subject to a simplified procedure as detailed in Article 3 of this Directive. U.K.

11. The application of these common principles shall lead to the Member State deciding whether or not a biocidal product can be authorised, such authorisation may include restrictions on use or other conditions. In certain cases the Member State may conclude that more data are required before an authorisation decision can be made. U.K.

12. During the process of evaluation and decision-making, Member States and applicants shall cooperate in order to resolve any questions on the data requirements quickly or to identify at an early stage any additional studies required, or to amend any proposed conditions for the use of the biocidal product or to modify its nature or its composition in order to ensure full compliance with the requirements of this Annex or of this Directive. The administrative burden, especially for small and medium-sized enterprises (SMEs), shall be kept to the minimum necessary without prejudicing the level of protection afforded to humans, animals and the environment. U.K.

13. The judgments made by the Member State during the evaluation and decision-making process must be based on scientific principles, preferably recognised at international level, and be made with the benefit of expert advice. U.K.

EVALUATION U.K.

General principles U.K.

14. The data submitted in support of an application for authorisation of a biocidal product shall be examined for completeness and overall scientific value by the receiving Member State. After acceptance of these data the Member State shall utilise them by carrying out a risk assessment based on the proposed use of the biocidal product. U.K.

15. A risk assessment on the active substance present in the biocidal product shall always be carried out. If there are, in addition, any substances of concern present in the biocidal product then a risk assessment shall be carried out for each of these. The risk assessment shall cover the proposed normal use of the biocidal product together with a realistic worst-case scenario including any relevant production and disposal issue either of the biocidal product itself or any material treated with it. U.K.

16. For each active substance and each substance of concern present in the biocidal product, the risk assessment shall entail a hazard identification and the establishment of appropriate no-observed-adverse-effect levels (NOAEL), where possible. It shall also include, as appropriate, a dose (concentration) — response (effect) assessment, together with an exposure assessment and a risk characterisation. U.K.

17. The results arrived at from a comparison of the exposure to the no-effect level concentrations for each of the active substances and any substances of concern shall be integrated to produce an overall risk assessment for the biocidal product. Where quantitative results are not available the results of the qualitative assessments shall be integrated in a similar manner. U.K.

18. The risk assessment shall determine: U.K.

(a)

the risk to humans and animals,

(b)

the risk to the environment,

(c)

the measures necessary to protect humans, animals and the general environment during both the proposed normal use of the biocidal product and in a realistic worst-case situation.

19. In certain cases it may be concluded that further data are required before a risk assessment can be finalised. Any such additional data requested shall be the minimum necessary to complete such a risk assessment. U.K.

Effects on humans U.K.

20. The risk assessment shall take account of the following potential effects arising from the use of the biocidal product and the populations liable to exposure. U.K.

21. The effects previously mentioned result from the properties of the active substance and any substance of concern present. They are: U.K.

• acute and chronic toxicity,

• irritation,

• corrosivity,

• sensitisation,

• repeated dose toxicity,

• mutagenicity,

• carcinogenicity,

• reproduction toxicity,

• neurotoxicity,

• any other special properties of the active substance or substance of concern,

• other effects due to physico-chemical properties.

22. The populations previously mentioned are: U.K.

• professional users,

• non-professional users,

• humans exposed indirectly via the environment.

23. The hazard identification shall address the properties and potential adverse effects of the active substance and any substances of concern present in the biocidal product. If this results in the biocidal product being classified according to the requirements of Article 20 of this Directive then dose (concentration) — response (effect) assessment, exposure assessment and risk characterisation shall be required. U.K.

24. In those cases where the test appropriate to hazard identification in relation to a particular potential effect of an active substance or a substance of concern present in a biocidal product has been conducted but the results have not lead to classification of the biocidal product then risk characterisation in relation to that effect shall not be necessary unless there are other reasonable grounds for concern, e.g. adverse environmental effects or unacceptable residues. U.K.

25. The Member State shall apply paragraphs 26 to 29 when carrying out a dose (concentration) — response (effect) assessment on an active substance or a substance of concern present in a biocidal product. U.K.

26. For repeated dose toxicity and reproductive toxicity the dose response relationship shall be assessed for each active substance or substance of concern and, where possible, the no-observed-adverse-effect level (NOAEL) identified. If it is not possible to identify a NOAEL, the lowest-observed-adverse-effect level (LOAEL) shall be identified. U.K.

27. For acute toxicity, corrosivity and irritation, it is not usually possible to derive a NOAEL or LOAEL on the basis of tests conducted in accordance with the requirements of this Directive. For acute toxicity, the LD50 (median lethal dose) or LC50 (median lethal concentration) value or, where the fixed dose procedure has been used, the discriminating dose shall be derived. For the other effects it shall be sufficient to determine whether the active substance or substance of concern has an inherent capacity to cause such effects during use of the product. U.K.

28. For mutagenicity and carcinogenicity it shall be sufficient to determine whether the active substance or substance of concern has an inherent capacity to cause such effects during use of the biocidal product. However, if it can be demonstrated that an active substance or a substance of concern identified as a carcinogen is non-genotoxic, it will be appropriate to identify a N(L)OAEL as described in paragraph 26. U.K.

29. With respect to skin sensitisation and respiratory sensitisation, in so far as there is no consensus on the possibility of identifying a dose/concentration below which adverse effects are unlikely to occur in a subject already sensitised to a given substance, it shall be sufficient to evaluate whether the active substance or substance of concern has an inherent capacity to cause such effects during use of the biocidal product. U.K.

30. Where toxicity data derived from observations of human exposure, e.g. information gained from manufacture, from poison centres or epidemiology surveys, are available special consideration shall be given to those data when carrying out the risk assessment. U.K.

31. An exposure assessment shall be carried out for each of the human populations (professional users, non-professional users and humans exposed indirectly via the environment) for which exposure to a biocidal product occurs or can reasonably be foreseen. The objective of the assessment shall be to makea quantitative or qualitative estimate of the dose/concentration of each active substance or substance of concern to which a population is, or may be exposed during use of the biocidal product. U.K.

32. The exposure assessment shall be based on the information in the technical dossier provided in conformity with Article 8 of this Directive and on any other available and relevant information. Particular account shall be taken, as appropriate, of: U.K.

• adequately measured exposure data,

• the form in which the product is marketed,

• the type of biocidal product,

• the application method and application rate,

• the physico-chemical properties of the product,

• the likely routes of exposure and potential for absorption,

• the frequency and duration of exposure,

• the type and size of specific exposed populations where such information is available.

33. Where adequately measured, representative exposure data are available, special consideration shall be given to them when conducting the exposure assessment. Where calculation methods are used for the estimation of exposure levels, adequate models shall be applied. U.K.

These models shall:

• make a best possible estimation of all relevant processes taking into account realistic parameters and assumptions,

• be subjected to an analysis taking into account possible elements of uncertainty,

• be reliably validated with measurements carried out under circumstances relevant for the use of the model,

• be relevant to the conditions in the area of use.

Relevant monitoring data from substances with analogous use and exposure patterns or analogous properties shall also be considered.

34. Where, for any of the effects set out in paragraph 21 a NOAEL or LOAEL had been identified, the risk characterisation shall entail comparison of the NOAEL or LOAEL with the evaluation of the dose/concentration to which the population will be exposed. Where a NOAEL or LOAEL cannot be established a qualitative comparison shall be made. U.K.

Effects on animals U.K.

35. Using the same relevant principles as described in the section dealing with effects on humans, the Member State shall consider the risks posed to animals from the biocidal product. U.K.

Effects on the environment U.K.

36. The risk assessment shall take account of any adverse effects arising in any of the three environmental compartments — air, soil and water (including sediment) — and of the biota following the use of the biocidal product. U.K.

37. The hazard identification shall address the properties and potential adverse effects of the active substance and any substances of concern present in the biocidal product. If this results in the biocidal product being classified according to the requirements of this Directive then dose (concentration) — response (effect) assessment, exposure assessment and risk characterisation shall be required. U.K.

38. In those cases where the test appropriate to hazard identification in relation to a particular potential effect of an active substance or a substance of concern present in a biocidal product has been conducted but the results have not led to classification of the biocidal product then riskcharacterisation in relation to that effect shall not be necessary unless there are other reasonable grounds for concern. Such grounds may derive from the properties and effects of any active substance or substance of concern in the biocidal product, in particular: U.K.

• any indications of bioaccumulation potential,

• the persistence characteristics,

• the shape of the toxicity/time curve in ecotoxicity testing,

• indications of other adverse effects on the basis of toxicity studies (e.g. classification as a mutagen),

• data on structurally analogous substances,

• endocrine effects.

39. A dose (concentration) — response (effect) assessment shall be carried out in order to predict the concentration below which adverse effects in the environmental compartment of concern are not expected to occur. This shall be carried out for the active substance and for any substance of concern present in the biocidal product. This concentration is known as the predicted no-effect concentration (PNEC). However, in some cases, it may not be possible to establish a PNEC and a qualitative estimation of the dose (concentration) — response (effect) then has to be made. U.K.

40. The PNEC shall be determined from the data on effects on organisms and ecotoxicity studies submitted in accordance with requirements of Article 8 of this Directive. It shall be calculated by applying an assessment factor to the values resulting from tests on organisms, e.g. LD50 (median lethal dose), LC50 (median lethal concentration), EC50 (median effective concentration), IC50 (concentration causing 50 % inhibition of a given parameter, e.g. growth), NOEL(C) (no-observed-effect level (concentration)), or LOEL(C) (lowest-observed-effect level (concentration)). U.K.

41. An assessment factor is an expression of the degree of uncertainty in extrapolation from test data on a limited number of species to the real environment. Therefore, in general, the more extensive the data and the longer the duration of the tests, the smaller is the degree of uncertainty and the size of the assessment factor. U.K.

The specifications for the assessment factors shall be elaborated in the notes for technical guidance which, to this end, shall be based particularly on the indications given in Commission Directive 93/67/EEC of 20 July 1993 laying down the principles for assessment of risks to man and environment from substances notified in accordance with Council Directive 67/548/EEC(6).

42. For each environmental compartment an exposure assessment shall be carried out in order to predict the concentration likely to be found of each active substance or substance of concern present in the biocidal product. This concentration is known as the predicted environmental concentration (PEC). However in some cases it may not be possible to establish a PEC and a qualitative estimate of exposure then has to be made. U.K.

43. A PEC, or where necessary a qualitative estimate of exposure, need only be determined for the environmental compartments to which emissions, discharges, disposal or distributions including any relevant contribution from material treated with biocidal products are known or are reasonably foreseeable. U.K.

44. The PEC, or qualitative estimation of exposure, shall be determined taking account of, in particular, and if appropriate: U.K.

• adequately measured exposure data,

• the form in which the product is marketed,

• the type of biocidal product,

• the application method and application rate,

• the physico-chemical properties,

• breakdown/transformation products,

• likely pathways to environmental compartments and potential for adsorption/desorption and degradation,

• the frequency and duration of exposure.

45. Where adequately measured, representative exposure data are available, special consideration shall be given to them when conducting the exposure assessment. Where calculation methods are used for the estimation of exposure levels, adequate models shall be applied. The characteristics of these models shall be as listed in paragraph 33. Where appropriate, on a case-by-case basis, relevant monitoring data from substances with analogous use and exposure patterns or analogous properties should also be considered. U.K.

46. For any given environmental compartment, the risk characterisation shall, as far as possible, entail comparison of the PEC with the PNEC so that a PEC/PNEC ratio may be derived. U.K.

47. If it has not been possible to derive a PEC/PNEC ratio, the risk characterisation shall entail a qualitative evaluation of the likelihood that an effect is occurring under the current conditions of exposure or will occur under the expected conditions of exposure. U.K.

Unacceptable effects U.K.

48. Data shall be submitted to and evaluated by the Member State to assess whether the biocidal product does not cause unnecessary suffering in its effect on target vertebrates. This shall include an evaluation of the mechanism by which the effect is obtained and the observed effects on the behaviour and health of the target vertebrates; where the intended effect is to kill the target vertebrate the time necessary to obtain the death of the target vertebrate and the conditions under which death occurs shall be evaluated. U.K.

49. The Member State shall, where relevant, evaluate the possibility of the development of resistance to an active substance in the biocidal product by the target organism. U.K.

50. If there are indications that any other unacceptable effects may occur the Member State shall evaluate the possibility of such effects occurring. An example of such an unacceptable effect would be an adverse reaction to fastenings and fittings used in wood following the application of a wood preservative. U.K.

Efficacy U.K.

51. Data shall be submitted and evaluated to ascertain if the efficacy claims of the biocidal product can be substantiated. Data submitted by the applicant or held by the Member State must be able to demonstrate the efficacy of the biocidal product against the target organism when used normally in accordance with the conditions of authorisation. U.K.

52. Testing should be carried out according to Community guidelines if these are available and applicable. Where appropriate, other methods can be used as shown in the list below. If relevant acceptable field data exist, these can be used. U.K.

• ISO, CEN or other international standard method

• national standard method

• industry standard method (accepted by Member State)

• individual producer standard method (accepted by Member State)

• data from the actual development of the biocidal product (accepted by Member State).

Summary U.K.

53. In each of the areas where risk assessments have been carried out, i.e. effects on man, animals, and the environment, the Member State shall combine the results for the active substance together with the results for any substance of concern to produce an overall assessment for the biocidal product itself. This should take account of any likely synergistic effects of the active substance(s) and substances of concern in the biocidal product. U.K.

54. For biocidal products containing more than one active substance any adverse effects shall also be combined to produce an overall effect for the biocidal product itself. U.K.

DECISION MAKING U.K.

General principles U.K.

55. Subject to paragraph 96, the Member State shall come to a decision regarding the authorisation for use of a biocidal product as a result of the integration of the risks arising from each active substance together with the risks from each substance of concern present in the biocidal product. The risk assessments shall cover normal use of the biocidal product together with a realistic worst-case scenario including any relevant disposal issue either of the biocidal product itself or any material treated with it. U.K.

56. In making a decision concerning authorisation, the Member State shall arrive at one of the following conclusions for each product type and for each area of use of the biocidal product for which application has been made: U.K.

1.

the biocidal product cannot be authorised;

2.

the biocidal product can be authorised subject to specific conditions/restrictions;

3.

more data is required before a decision on authorisation can be made.

57. If the conclusion arrived at by the Member State is that additional information or data are required before an authorisation decision can be made, then the need for any such information or data shall be justified. This additional information or data shall be the minimum necessary to carry out a further appropriate risk assessment. U.K.

58. The Member State shall comply with the principles of mutual recognition as detailed in Article 4 of this Directive. U.K.

59. The Member State shall apply the rules concerning the concept of ‘frame formulations’ when making an authorisation decision on a biocidal product. U.K.

60. The Member State shall apply the rules concerning the concept of ‘low risk’ products when making an authorisation decision on such a biocidal product. U.K.

61. The Member State shall only grant authorisation to those biocidal products which, when used according to their conditions of authorisation, do not present an unacceptable risk to humans, animals or the environment, are efficacious and which contain active substances permitted at Community level to be used in such biocidal products. U.K.

62. The Member State shall impose, where appropriate, conditions or restrictions when giving authorisations. The nature and severity of these shall be selected on the basis of, and be appropriate to, the nature and extent of the expected advantages and the risks likely to arise from the use of the biocidal product. U.K.

63. In the decision-making process the Member State shall take into consideration the following: U.K.

• the results of the risk assessment, in particular the relationship between exposure and effect,

• the nature and severity of the effect,

• the risk management which can be applied,

• the field of use of the biocidal product,

• the efficacy of the biocidal product,

• the physical properties of the biocidal product,

• the benefits of using the biocidal product.

64. The Member State shall, when taking a decision concerning the authorisation of a biocidal product, take into account the uncertainty arising from the variability in the data used in the evaluation and decision-making process. U.K.

65. The Member State shall prescribe that biocidal products shall be used properly. Proper use shall include application at an efficacious dose and minimisation of use of biocidal products where possible. U.K.

66. The Member State shall take the necessary measures to ensure that the applicant proposes a label, and, where relevant, the safety-data sheet, for the biocidal product which: U.K.

• fulfils the requirements of Articles 20 and 21 of this Directive,

• contains the information on the protection of users required by Community legislation on worker protection,

• specifies in particular the conditions or restrictions under which the biocidal product may or may not be used.

Before issuing an authorisation the Member State shall confirm that these requirements must be satisfied.

67. The Member State shall take the necessary measures to ensure that the applicant proposes packaging and, where appropriate, the procedures for destruction or decontamination of the biocidal product and its packaging or any other relevant material associated with the biocidal product, which conforms to the relevant regulatory provisions. U.K.

Effects on humans U.K.

68. The Member State shall not authorise a biocidal product if the risk assessment confirms that, in foreseeable application including a realistic worst possible scenario, the product presents an unacceptable risk to humans. U.K.

69. The Member State shall consider possible effects on all human populations, namely professional users, non-professional users and humans exposed directly or indirectly through the environment when making a decision on the authorisation of a biocidal product. U.K.

70. The Member State shall examine the relationship between the exposure and the effect, and use this in the decision-making process. A number of factors need to be considered when examining this relationship and one of the most important is the nature of the adverse effect of the substance. These effects include acute toxicity, irritancy, corrosivity, sensitisation, repeated dose toxicity, mutagenicity, carcinogenicity, neurotoxicity, reproduction toxicity together with physico-chemical properties, and any other adverse properties of the active substance or substance of concern. U.K.

71. The Member State shall, where possible, compare the results obtained with those obtained from previous risk assessments for an identical or similar adverse effect and decide on an appropriate margin of safety (MOS) when making an authorisation decision. U.K.

An appropriate MOS is typically 100 but an MOS higher or lower than this may be appropriate depending on, among other things, the nature of the critical toxicological effect.

72. The Member State shall, if appropriate, impose, as a condition of authorisation, the wearing of personal protective equipment such as respirators, breathing-masks, overalls, gloves and goggles in order to reduce exposure for professional operators. Such equipment must be readily available to them. U.K.

73. If for non-professional users the wearing of personal protective equipment would be the only possible method for reducing exposure, the product shall not normally be authorised. U.K.

74. If the relationship between the exposure and the effect cannot be reduced to an acceptable level then no authorisation can be given by the Member State for the biocidal product. U.K.

75. No biocidal product classified according to Article 20(1) of this Directive as toxic, very toxic or as a category 1 or 2 carcinogen, or as a category 1 or 2 mutagen, or classified as toxic for reproduction category 1 or 2, shall be authorised for use by the general public. U.K.

Effects on animals U.K.

76. The Member State shall not authorise a biocidal product if the risk assessment confirms that, in normal use, the biocidal product presents an unacceptable risk to non-target animals. U.K.

77. Using the same relevant criteria as described in the section dealing with effects on humans, the Member State shall consider the risks posed to animals from the biocidal product when making an authorisation decision. U.K.

Effects on the environment U.K.

78. The Member State shall not authorise a biocidal product if the risk assessment confirms that the active substance, or any substance of concern, or any degradation, or reaction product presents an unacceptable risk in any of the environmental compartments, water (including sediment), soil and air. This shall include the assessment of risks to non-target organisms in these compartments. U.K.

In considering whether there is an unacceptable risk Member States shall, when coming to a final decision in accordance with paragraph 96, take into account the criteria in paragraphs 81 to 91.

79. The basic tool used in the decision making is the PEC/PNEC ratio or, if this is not available, a qualitative estimation. Due consideration shall be given to the accuracy of this ratio due to variability in the data used both in measurements of concentration and of estimation. U.K.

In the determination of the PEC the most appropriate model should be used taking into account the environmental fate and behaviour of the biocidal product.

80. For any given environmental compartment if the PEC/PNEC ratio is equal to or less than 1 the risk characterisation shall be that no further information and/or testing are necessary. U.K.

If the PEC/PNEC ratio is greater than 1 the Member State shall judge, on the basis of the size of that ratio and on other relevant factors, if further information and/or testing are required to clarify the concern or if risk reduction measures are necessary or if the product cannot be given an authorisation at all. Relevant factors to be considered are those previously mentioned in paragraph 38.

Water U.K.

81. The Member State shall not authorise a biocidal product, if under the proposed conditions of use, the foreseeable concentration of the active substance or of any other substance of concern or of relevant metabolites or breakdown or reaction products in water (or its sediments) has an unacceptable impact on non-target species in the aquatic, marine or estuarine environment unless it is scientifically demonstrated that under relevant field conditions there is no unacceptable effect. U.K.

82. The Member State shall not authorise a biocidal product if, under the proposed conditions of use, the foreseeable concentration of the active substance or of any other substance of concern or of relevant metabolites or breakdown or reaction products in groundwater exceeds the lower of the following concentrations: U.K.

(a)

the maximum permissible concentration laid down by Directive 80/778/EEC, or

(b)

the maximum concentration as laid down following the procedure for including the active substance in Annex I, IA or IB to this Directive, on the basis of appropriate data, in particular toxicological data

unless it is scientifically demonstrated that under relevant field conditions the lower concentration is not exceeded.

83. The Member State shall not authorise a biocidal product if the foreseeable concentration of the active substance or a substance of concern or of relevant metabolites, breakdown or reaction products to be expected in surface water or its sediments after use of the biocidal product under the proposed conditions of use: U.K.

• exceeds, where the surface water in or from the area of envisaged use is intended for the abstraction of drinking water, the values fixed by

  • Council Directive 75/440/EEC of 16 June 1975 concerning the quality required of surface water intended for the abstraction of drinking water in the Member States(7),

  • Directive 80/778/EEC or

• has an impact deemed unacceptable on non-target species

unless it is scientifically demonstrated that under relevant field conditions this concentration is not exceeded.

84. The proposed instructions for use of the biocidal product, including procedures for cleaning application equipment, must be such that the likelihood of accidental contamination of water or its sediments is minimised. U.K.

Soil U.K.

85. Where unacceptable contamination of soil is likely to occur, the Member State shall not authorise a biocidal product if the active substance or substance of concern contained in it, after use of the biocidal product: U.K.

• during tests in the field, persists in soil for more than one year, or

• during laboratory tests, forms non-extractable residues in amounts exceeding 70 % of the initial dose after 100 days with a mineralisation rate of less than 5 % in 100 days,

• has unacceptable consequences or effects on non-target organisms,

unless it is scientifically demonstrated that under field conditions there is no unacceptable accumulation in soil.

Air U.K.

86. The Member State shall not authorise a biocidal product where there is a foreseeable possibility of unacceptable effects on the air compartment unless it is scientifically demonstrated that under relevant field conditions there is no unacceptable effect. U.K.

Effects on non-target organisms U.K.

87. The Member State shall not authorise a biocidal product where there is a reasonably foreseeable possibility of non-target organisms being exposed to the biocidal product if for any active substance or substance of concern: U.K.

• the PEC/PNEC is above 1 unless it is clearly established in the risk assessment that under field conditions no unacceptable effects occur after use of the biocidal product according to the proposed conditions of use, or

• the bioconcentration factor (BCF) related to fat tissues in non-target vertebrates is above 1 unless it is clearly established in the risk assessment that under field conditions no unacceptable effects occur, either directly or indirectly, after use of the product according to the proposed conditions of use.

88. The Member State shall not authorise a biocidal product where there is a reasonably foreseeable possibility of aquatic organisms including marine and estuarine organisms being exposed to the biocidal product if for any active substance or substance of concern in it: U.K.

• the PEC/PNEC is above 1 unless it is clearly established in the risk assessment that under field conditions the viability of aquatic organisms including marine and estuarine organisms is not threatened by the biocidal product according to the proposed conditions of use, or

• the bioconcentration factor (BCF) is greater than 1 000 for substances which are readily biodegradable or greater than 100 for those which are not readily biodegradable unless it is clearly established in the risk assessment that under field conditions no unacceptable impact, either directly or indirectly, occurs on the viability of exposed organisms including marine and estuarine organisms after use of the biocidal product according to the proposed conditions of use.

By way of derogation from this paragraph, Member States may, however, authorise an anti-fouling product used on commercial, public service and naval seagoing vessels for a period of up to 10 years from the date on which this Directive enters into force if similar fouling control cannot be achieved by other practicable means. When implementing this provision, Member States shall, if appropriate, take into account relevant International Maritime Organisation (IMO) resolutions and recommendations.

89. The Member State shall not authorise a biocidal product where there is a reasonably foreseeable possibility of micro-organisms in sewage treatment plants being exposed to the biocidal product if for any active substance, substance of concern, relevant metabolite, breakdown or reaction product the PEC/PNEC ratio is above 1 unless it is clearly established in the risk assessment that under field conditions no unacceptable impact, either directly or indirectly, occurs on the viability of such micro-organisms. U.K.

Unacceptable effects U.K.

90. If the development of resistance to the active substance in the biocidal product is likely the Member State shall take steps to minimise the consequences of this resistance. This may involve modification of the conditions of authorisation or even refusal of any authorisation. U.K.

91. An authorisation for a biocidal product intended to control vertebrates shall not be given unless: U.K.

• death is synchronous with the extinction of consciousness, or,

• death occurs immediately, or,

• vital functions are reduced gradually without signs of obvious suffering.

For repellent products, the intended effect shall be obtained without unnecessary suffering and pain for the target vertebrate.

Efficacy U.K.

92. Member States shall not authorise a biocidal product which does not possess acceptable efficacy when used in accordance with the conditions specified on the proposed label or with other conditions of authorisation. U.K.

93. The level, consistency and duration of protection, control or other intended effects must, as a minimum, be similar to those resulting from suitable reference products, where such products exist, or to other means of control. Where no reference products exist, the biocidal product must give a defined level of protection or control in the areas of proposed use. Conclusions as to the performance of the biocidal product must be valid for all areas of proposed use and for all areas in the Member State except where the proposed label prescribes that the biocidal product is intended for use in specific circumstances. Member States shall evaluate dose response data generated in trials (which must include an untreated control) involving dose rates lower than the recommended rate, in order to assess if the recommended dose is the minimum necessary to achieve the desired effect. U.K.

Summary U.K.

94. In each of the areas where risk assessments have been carried out, i.e. effects on humans, animals, and the environment, the Member State shall combine the conclusions arrived at for the active substance and the substances of concern to produce an overall conclusion for the biocidal product itself. A summary should also be made of the efficacy assessment and of the unacceptable effects. U.K.

The result shall be:

• a summary of the effects of the biocidal product on humans,

• a summary of the effects of the biocidal product on animals,

• a summary of the effects of the biocidal product on the environment,

• a summary of the efficacy assessment,

• a summary of the unacceptable effects.

OVERALL INTEGRATION OF CONCLUSIONS U.K.

95. The Member State shall combine the individual conclusions arrived at with regard to effects of the biocidal product on the three sectors namely, humans, animals and the environment to arrive at an overall conclusion for the global effect of the biocidal product. U.K.

96. The Member State shall then take due consideration of any relevant unacceptable effects, the efficacy of the biocidal product and the benefits of using the biocidal product before taking an authorisation decision on the biocidal product. U.K.

97. The Member State shall ultimately decide whether or not the biocidal product can be authorised and whether this authorisation shall be subject to any restrictions or conditions in conformity with this Annex and this Directive. U.K.

(1)

OJ L 154, 5.6.1992, p. 1.

(2)

OJ L 229, 30.8.1980, p. 11. Directive as last amended by Directive 91/692/EEC (OJ L 377, 31.12.1991, p. 48).

(3)

OJ L 20, 26.1.1980, p. 43.

(4)

[F55 OJ L 262, 17.10.2000, p. 21 .

(5)

OJ L 200, 30.7.1999, p. 1 . Directive as last amended by Commission Directive 2006/8/EC ( OJ L 19, 24.1.2006, p. 12 ).]

(6)

OJ L 227, 8.9.1993, p. 9.

(7)

OJ L 194, 25.7.1975, p. 26. Directive as last amended by Directive 91/692/EEC (OJ L 377, 31.12.1991, p. 48).

Textual Amendments

F55 Substituted by Commission Directive 2006/50/EC of 29 May 2006 amending Annexes IVA and IVB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (Text with EEA relevance).